Progress, Potential, and Possibilities

Send us Fan MailMost of us think of medicine as something we take every day - a statin, a blood pressure pill, or perhaps a monthly injection. But what if those lifelong treatments eventually become obsolete? What if one carefully targeted gene edit could dramatically reduce your risk of heart disease for decades? Dr. Trevor Martin, Ph.D. is the Co-Founder and Chief Executive Officer of Mammoth Biosciences ( https://mammoth.bio/ ), a pioneering biotechnology company developing next-generation CRISPR genome editing technologies for potentially curative medicines. He co-founded the company in 2017 alongside Nobel Prize-winning CRISPR pioneer Dr. Jennifer Doudna and an interdisciplinary team of leading scientists with the goal of building more precise, versatile, and clinically practical gene editing systems.Dr. Martin earned his undergraduate degree in Molecular Biology with honors from Princeton University before completing a Ph.D. in Genetics and Statistics at Stanford University, where his research focused on quantitative genetics, genomics, and computational biology. His scientific background in statistics and genetics has shaped Mammoth's unique approach to developing smaller CRISPR enzymes capable of reaching tissues and diseases that have been difficult to target with first-generation technologies.Under Dr. Martin's leadership, Mammoth has grown into one of the world's leading CRISPR companies, raising more than $465 million, achieving a valuation exceeding $1 billion, and establishing strategic collaborations with companies including Vertex Pharmaceuticals, Bayer, and Regeneron Pharmaceuticals.Today, Mammoth is advancing a pipeline of in vivo gene editing therapies, including programs targeting cardiovascular disease through permanent editing of the APOC3 gene - a potential one-time treatment approach aimed at dramatically reducing triglycerides and long-term cardiovascular risk. Beyond therapeutics, the company's CRISPR platform also extends into diagnostics and genome engineering technologies that may reshape medicine over the coming decades.Dr. Martin has been recognized as an EY Entrepreneur of the Year®, Forbes 30 Under 30, and Fortune 40 Under 40 honoree for his contributions to biotechnology and scientific entrepreneurship.#CRISPR #GeneEditing #TrevorMartin #MammothBiosciences #JenniferDoudna #Biotechnology #GenomeEditing #HeartDisease #Longevity #FutureOfMedicine #PrecisionMedicine #Genetics #DNA #HealthInnovation #MedicalBreakthrough #CardiovascularDisease #SciencePodcast #Biotech #Innovation #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailThe same technologies that could transform medicine, agriculture, and manufacturing could also reshape global security. Understanding the future of biotechnology requires scientists who can bridge discovery, engineering, and responsibility.Today on Progress, Potential, and Possibilities, we're joined by a true pioneer at the nexus of biotechnology and national security. Dr. Jessica Dymond, Ph.D is the Vice President of Technology at In-Q-Tel ( https://www.iqt.org/ ), a not-for-profit venture fund that invests in companies advancing the strategic priorities of U.S. Intelligence Community, where she provides technical and strategic leadership to accelerate emerging biotechnologies that address some of the most critical challenges to national and global security.Before In-Q-Tel, Dr. Dymond served as Chief Scientist for Physical and Life Sciences at the Johns Hopkins University Applied Physics Laboratory, where she led an interdisciplinary portfolio spanning biological sensing, genomic surveillance, microbiome engineering, and synthetic biology. She founded the Lab's Biological Sciences group and spearheaded initiatives to anticipate, assess, and mitigate emerging biological threats while strengthening global health security.Formally trained as a synthetic biologist, Dr. Dymond earned her Ph.D. from the Johns Hopkins University School of Medicine, completed a postdoctoral fellowship in functional genomics at the U.S. Department of Agriculture, and has contributed to groundbreaking research, including the design of synthetic yeast genomes and combinatorial genomic diversity. She also serves on the editorial board of Synthetic Biology from Oxford University Press.Dr. Dymond's career embodies the bridge between cutting-edge science, technology strategy, and real-world impact - protecting health, security, and society through innovation at the molecular frontier.#SyntheticBiology #Biotechnology #Biosecurity #FutureOfBiology #GenomeEngineering #Genomics #DNA #GeneticEngineering #ArtificialBiology #BiologyRevolution #LifeSciences #FutureTechnology #EmergingTechnologies #ScienceInnovation #Innovation #NationalSecurity #GlobalHealthSecurity #PandemicPreparedness #AIandBiology #Bioengineering #SyntheticGenomics #CRISPR #GeneticTechnology #HealthcareInnovation #ScientificDiscovery #TechnologyTrends #ProgressPotentialAndPossibilitiesSupport the show

Send us Fan MailWe spend billions of dollars each year funding scientific discovery - but what happens if the people making those discoveries can't communicate them? Today we're exploring why communication may be just as important as innovation itself, and why some of the world's brightest scientists never receive the recognition their work deserves.Nancy Ancowitz ( https://www.nancyancowitz.com/ ) is career strategist, executive presentation coach, author, educator, and one of the country's leading experts on helping professionals communicate their expertise with clarity, confidence, and authenticity.Nancy has spent more than two decades teaching communication, presentation skills, and career strategy at New York University ( https://www.sps.nyu.edu/faculty-directory/10734-nancy-h-ancowitz.html ) while coaching everyone from emerging professionals to CEOs on how to translate knowledge into influence. Nancy is the author of the acclaimed Self-Promotion for Introverts® ( https://www.amazon.com/Self-Promotion-Introverts-Quiet-Guide-Getting-ebook/dp/B00394U8DS?ref_=ast_author_dp&th=1&psc=1 ), recognized by Publishers Weekly as one of the year's best business books, as well as Zoom to Success and Business Writing: Say More With Less.Before launching her coaching practice, Nancy spent twelve years on Wall Street, leading marketing communications for multibillion-dollar businesses as a Vice President at JPMorgan Chase and earlier at Citibank, where she was recognized for innovation in global marketing communications. Along the way, her insights have appeared in The New York Times, The Wall Street Journal, and Psychology Today, and she has spoken at organizations ranging from the National Institutes of Health to the Federal Reserve Bank of New York.Today, we're taking Nancy's work in a slightly different direction. Here on Progress, Potential and Possibilities, we spend much of our time with scientists, physicians, engineers, biotech founders, and technology innovators who are developing extraordinary breakthroughs - but often struggle to communicate those breakthroughs beyond their laboratories, companies, and research institutions.In an age where groundbreaking discoveries compete with endless streams of information, social media, and artificial intelligence, is communication becoming just as important as innovation itself? Can brilliant ideas change the world if their creators never learn to tell their story?We explore why communication, authenticity, and thoughtful self-promotion may be some of the most underrated drivers of scientific and technological progress.#ScienceCommunication #STEM #Innovation #Leadership #PublicSpeaking #CommunicationSkills #Scientists #Biotechnology #ArtificialIntelligence #InnovationLeadership #Entrepreneurship #CareerDevelopment #PresentationSkills #PersonalBranding #AuthenticLeadership #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailWhat happens when you step back from individual biotech companies and look at the entire industry?Today's guest has spent decades connecting biotech CEOs, investors, pharmaceutical leaders, and innovators from around the world - giving her a rare front-row seat to the trends shaping the future of medicine. From AI and TechBio to venture capital, partnering, and breakthrough therapies, we're exploring where biotech is really headed next.Sara Jane Demy is the Founder and CEO of Demy-Colton ( https://demy-colton.com/ ), one of the most influential organizations in life sciences events and ecosystem connectivity.For more than two decades, Sara has operated at the intersection of biotech innovation, venture capital, and pharma partnering - first at the Biotechnology Innovation Organization (BIO), where she helped launch major industry conferences including BIO CEO & Investor Conference, BIO Investor Forum, BIO Asia, and helped develop the partnering systems now widely used across the industry.Sara later founded Demy-Colton, which runs major industry convenings such as Biotech Showcase, BioFuture, and the Global Biotech CEO Summit - bringing together thousands of CEOs, investors, and BD leaders across the global biotech ecosystem.What makes Sara particularly unique is that she doesn't sit inside a single company or investment fund - she sits across the entire system. She has a rare, real-time view of how biotech narratives, capital flows, and strategic priorities are shifting across hundreds of companies and investors at once.And that's what we're going to explore today: not one company, but the state of biotech itself - what's changing, what's breaking, and what's emerging next.#Biotech #HealthcareInnovation #Pharma #DrugDiscovery #Biotechnology #ArtificialIntelligence #TechBio #PrecisionMedicine #LifeSciences #Innovation #MedicalResearch #FutureOfMedicine #Healthcare #Science #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailFor most of human history, scientists believed that once a cell became a skin cell, a neuron, or a heart cell, that identity was permanent. Then a group of researchers discovered something extraordinary: cells could be reset. My guest today was there when that discovery happened.Dr. Koji Tanabe, Ph.D. is Founder and CEO of I Peace ( https://ipeace.com/en/ ), one of the world's leading companies advancing induced pluripotent stem cell - or iPSC - technology from the research laboratory into scalable clinical manufacturing.Dr. Tanabe occupies a truly unique place in modern biomedical history. He earned his Ph.D. in the laboratory of Nobel Laureate Dr. Shinya Yamanaka at Kyoto University and was the second author on the landmark scientific paper that first demonstrated the successful creation of human induced pluripotent stem cells - a discovery that fundamentally changed regenerative medicine and ultimately earned Dr. Yamanaka the 2012 Nobel Prize.After helping establish one of the most important technologies in modern biology, Dr. Tanabe continued his work at Stanford University in the laboratory of Dr. Marius Wernig, a pioneer of direct cellular reprogramming, where he investigated how mature blood cells can be directly converted into neurons and explored the molecular mechanisms that govern cellular identity.In 2015, Dr. Tanabe founded I Peace with an ambitious vision: to make clinical-grade iPS cells accessible at industrial scale. Today, the company has developed automated GMP manufacturing platforms capable of producing personalized and clinical-grade iPS cells for researchers, pharmaceutical companies, and regenerative medicine programs around the world.On the episode we'll explore how far the field has come since those first groundbreaking experiments nearly two decades ago, where regenerative medicine stands today, the growing role of iPS cells in drug discovery and transplantation, the excitement surrounding in vivo reprogramming and partial cellular rejuvenation, and what may ultimately become possible when every individual has access to their own personalized stem cell bank.Important Episode Links - Future Medicine Lab with Koji Tanabe YouTube Channel -https://www.youtube.com/@FutureMedicineLabMy Peace (a service from I Peace) - Personal iPS Cell Banking Service - https://mypeace-personal-ipscbanking.com/en/#iPSC #StemCells #RegenerativeMedicine #CellularReprogramming #ShinyaYamanaka #NobelPrize #Biotechnology #Biotech #Longevity #AgingResearch #FutureMedicine #PrecisionMedicine #DrugDiscovery #CellTherapy #GeneEngineering #BiomedicalResearch #LifeSciences #HealthcareInnovation #MedicalInnovation #Science #Technology #Innovation #FutureOfMedicine #StemCellResearch #HumanBiology #SyntheticBiology #AIinMedicine #PharmaInnovation #DiseaseModeling #RegenerativeTherapySupport the show

Send us Fan MailHeart disease remains the leading cause of death worldwide, and one of its most important modifiable risk factors is elevated LDL cholesterol - the so-called "bad cholesterol." While statins have transformed cardiovascular care for decades, and newer therapies like injectable PCSK9 inhibitors have provided additional options, millions of patients still struggle to achieve recommended LDL cholesterol targets.In fact, despite the availability of effective therapies, roughly seventy percent of patients receiving cholesterol-lowering treatment still fail to reach guideline-recommended LDL cholesterol levels. The reasons are complex - from biology and treatment intensity to adherence and convenience - but the result is the same: preventable heart attacks, strokes, and cardiovascular deaths continue to occur.Now, a new chapter is beginning. Following years of clinical development, the FDA has approved LIPFENDRA™ (enlicitide), the first oral PCSK9 inhibitor, introducing an entirely new approach to LDL cholesterol reduction ( https://www.lipfendra.com/ ).Joining us today is someone uniquely qualified to help us understand what this approval means for physicians and patients.Dr. Norman Lepor, MD is Founder and Director of the National Heart Institute ( https://nationalheartinstitute.org/about/meet-our-team ), Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA, and an Attending Cardiologist at the Smidt Heart Institute at Cedars-Sinai ( https://www.cedars-sinai.org/provider/norman-lepor-106852.html ). A graduate of Johns Hopkins School of Medicine, Dr. Lepor has spent more than four decades advancing cardiovascular medicine through patient care, education, and clinical research. He has served as principal investigator on more than sixty clinical trials, authored dozens of influential scientific publications, and has been recognized by U.S. News & World Report as one of America's leading cardiologists. Throughout his career he has also been a champion for women's cardiovascular health and improving access to cutting-edge care for underserved populations.Today we'll discuss why LDL cholesterol remains such a difficult public health challenge, what we've learned over the past three decades of lipid management, how oral PCSK9 inhibition works, and what this newly approved therapy may mean for the future of preventing heart attacks and strokes.#HeartHealth #Cholesterol #LDL #Cardiology #HeartDisease #Prevention #PreventiveMedicine #LIPFENDRA #Enlicitide #PCSK9 #PrecisionMedicine #Longevity #CardiovascularHealth #MedicalInnovation #Biotech #FutureOfMedicine #HealthyAging #SciencePodcast #ProgressPotentialPossibilities #PPPPodcastSupport the show

Send us Fan MailWhat if I told you there is a major genetic risk factor for heart attacks and strokes that affects roughly one in five people worldwide - but most people have never heard of it, and it isn't measured on a standard cholesterol test? Today we're exploring Lp(a), the hidden cardiovascular risk factor that could reshape the future of heart disease prevention.Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P., is Senior Vice President and Chief Medical Officer of Amgen ( https://www.amgen.com/about/leadership/senior-management/paul-burton ).Dr. Burton has built one of the most remarkable careers in modern medicine and biotechnology. After training as a physician and cardiovascular surgeon in the United Kingdom and earning a Ph.D. in molecular and cellular biology from Imperial College London, he transitioned into the biotechnology industry, where he has spent more than two decades leading the development of innovative medicines across cardiovascular disease, oncology, infectious disease, metabolic disorders and RNA therapeutics.Before returning to Amgen as Chief Medical Officer in 2023, Dr. Burton served as Chief Medical Officer of Moderna during one of the most consequential periods in modern public health, overseeing global medical strategy and pharmacovigilance. Prior to that he spent sixteen years at Johnson & Johnson, ultimately serving as Chief Global Medical Affairs Officer while helping pioneer digital medicine initiatives, including collaborations exploring virtual clinical trials.Today, Dr. Burton leads Amgen's worldwide medical organization, helping guide one of the industry's broadest research pipelines while translating breakthrough science into therapies that can improve - and potentially save - millions of lives.One of those efforts is Amgen's ambitious work targeting lipoprotein(a), or Lp(a), a genetically inherited cardiovascular risk factor affecting roughly one in five people worldwide. Through its investigational siRNA therapy olpasiran and the expansive OCEAN(a) clinical program, Amgen hopes to answer one of the biggest remaining questions in preventive cardiology: can dramatically lowering Lp(a) prevent heart attacks and strokes?Today we'll explore Dr. Burton's fascinating career, what it means to lead medical strategy at one of biotechnology's largest innovators, and why the next decade may fundamentally reshape how we prevent cardiovascular disease.#Cardiology #HeartDisease #LpA #LipoproteinA #PrecisionMedicine #RNAmedicine #GeneSilencing #Biotechnology #Biotech #Amgen #DrugDiscovery #PharmaceuticalInnovation #FutureOfMedicine #CardiovascularHealth #HeartHealth #MedicalInnovation #HealthcareInnovation #PreventiveMedicine #Genomics #SiRNA #LongevityScience #RegenerativeMedicine #ClinicalTrials #Pharma #LifeSciences #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailFor decades we've measured obesity using one simple number on a scale - but what if that's the wrong metric? Today, one of the world's leading experts in genetics explains why the future of obesity medicine may not be about losing more weight, but about losing the right kind of fat while preserving the muscle that keeps us healthy.Dr. Erik Ingelsson, MD, PhD is a physician-scientist and internationally recognized leader in human genetics, genomics, and metabolic disease research. He currently serves as Chief Scientific Officer at Wave Life Sciences ( https://wavelifesciences.com/ ), where he leads the development of next-generation RNA medicines designed to address major unmet medical needs.Before joining Wave, Dr. Ingelsson served as Senior Vice President and Head of Target Discovery at GSK, where he led large-scale efforts integrating human genetics, functional genomics, computational biology, and molecular science to discover and validate new drug targets across therapeutic areas.Prior to his transition into industry, Dr. Ingelsson was Professor of Medicine at Stanford University, where his laboratory used human genetics and functional genomics to uncover new biological mechanisms underlying insulin resistance, obesity, metabolic disease, and cardiovascular risk.Over his career, Dr. Ingelsson has authored more than 400 peer-reviewed scientific publications and has become one of the leading voices in translating insights from human genetic variation into new medicines.At Wave, Dr. Ingelsson  is helping pioneer a new approach to obesity treatment: targeting the biology of harmful fat accumulation rather than simply focusing on the number on the scale.Today we'll discuss the genetics behind obesity, the promise of RNA medicines, why visceral fat may be the true therapeutic target, and whether the next generation of obesity treatments will move beyond weight loss toward healthier body composition.#Obesity #GLP1 #WeightLoss #VisceralFat #MetabolicHealth #RNAMedicine #Genetics #PrecisionMedicine #Longevity #HeartHealth #Diabetes #HumanGenetics #Biotechnology #DrugDiscovery #MuscleHealth #BodyComposition #CardiometabolicHealth #WaveLifeSciences #SciencePodcast #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailEvery year, nearly 700 million people around the world are infected by norovirus. Most people know it as a miserable few days of vomiting and diarrhea - but for transplant patients, cancer patients, and other immunocompromised individuals, it can become a chronic and potentially life-threatening infection. And despite decades of research, we still have no approved antiviral treatment. Today we're exploring the science behind the race to change that.James Sapirstein is Chief Executive Officer of Cocrystal Pharma ( https://www.cocrystalpharma.com/ ) and one of the biotechnology industry's most experienced commercialization executives.Throughout a career spanning more than four decades, James has participated in or led an extraordinary twenty-three pharmaceutical product launches while building and leading multiple biotechnology companies. He has served as CEO of Cocrystal Pharma, Contravir Pharmaceuticals, Tobira Therapeutics, First Wave BioPharma, and several other innovative life science organizations. Earlier in his career James held senior leadership roles at Bristol-Myers Squibb, Gilead Sciences, Serono Laboratories, Roche, and Eli Lilly, helping bring important therapies for infectious disease and other major conditions to patients around the world. Beyond industry, James has served on numerous biotechnology boards, including the Biotechnology Innovation Organization and BioNJ, making him one of the most respected leaders in the biotechnology ecosystem.James received a BS (Pharmacy) from Rutgers University and an MBA from Fairleigh Dickinson University.Dr. Sam Lee, Ph.D. is President and Chief Scientific Officer of Cocrystal Pharma. Dr. Lee has devoted more than twenty-five years to discovering next-generation antiviral medicines. Before joining Cocrystal, he led anti-infective drug discovery efforts at ICOS Corporation, where he pioneered the integration of protein crystallography and structure-based screening technologies into pharmaceutical research. His scientific work contributed to the development of PI3K delta inhibitors that ultimately led to an FDA-approved therapy. Dr. Lee earned his Ph.D. in Biological Sciences from the University of Notre Dame before completing postdoctoral research in viral biochemistry at Stanford University under renowned molecular biologist Dr. I. R. Lehman. His career has focused on understanding viruses at the atomic level to design highly targeted antiviral drugs capable of overcoming viral evolution and resistance.#Norovirus #AntiviralResearch #DrugDiscovery #Biotechnology #Biotech #PharmaInnovation #RNAViruses #ViralDiseases #InfectiousDisease #PublicHealth #StructureBasedDrugDiscovery #PrecisionMedicine #MedicinesOfTheFuture #FutureOfHealthcare #BiomedicalResearch #PharmaceuticalInnovation #ClinicalTrials #PandemicPreparedness #HealthcareInnovation #ScienceAndTechnology #ProgressPotentialAndPossibilities #PPPSupport the show

Send us Fan MailWhen most people hear the word "nuclear," they think of power plants and clean energy production. But every day, nuclear science is helping diagnose and treat millions of cancer patients around the world. Today, we're exploring one of the powerful new tools in our fight against cancer: medical isotopes. Our guest today is James Scongack, Chair of the Canadian Nuclear Isotope Council ( https://www.canadianisotopes.ca/ ), a national not-for-profit advocacy organization that supports over 120 members from across science, academia, healthcare, and nuclear-sector organizations dedicated to maintaining Canada's position as a global leader in the production of life-saving isotopes. The CNIC raises awareness and advocates for long-term policies that support health-care innovation and will save countless lives for decades to come. Under James's leadership, the CNIC launched its ambitious "Isotopes for Hope" campaign ( https://www.canadianisotopes.ca/isotopes-for-hope-campaign/ ), with the goal of doubling Canada's isotope production by 2030 while improving cancer care both domestically and internationally.Beyond his work at the CNIC, he also serves as the Chief Operating Officer and Executive Vice President at Bruce Power ( https://www.brucepower.com/ ), home to one of the world's largest operating nuclear generating facilities and Canada's largest private-sector electricity infrastructure project. During more than two decades at Bruce Power, James has helped lead one of the most remarkable transformations in modern nuclear energy - from extending the operating life of the Bruce site through a multi-billion-dollar refurbishment program, to expanding its role as one of the world's premier producers of medical isotopes that are helping diagnose and treat cancer around the globe.James also serves as Chair of the Pediatric Oncology Group of Ontario ( https://www.pogo.ca/ ) and the Nuclear Innovation Institute ( https://www.nuclearinnovationinstitute.ca/ ), reflecting his deep commitment to improving healthcare through science and innovation.Recognized as one of Canada's Top 40 Under 40, recipient of the King Charles III Coronation Medal, and honored by The Globe and Mail's Best Executive Awards, James has become one of the leading voices on the future of nuclear energy - not only as a source of clean electricity, but as a platform for advancing medicine, biotechnology, and global health.#NuclearMedicine #MedicalIsotopes #CancerTreatment #PrecisionMedicine #Radiopharmaceuticals #Theranostics #CancerResearch #NuclearEnergy #HealthcareInnovation #Biotechnology #Radiology #Oncology #MedicalInnovation #BrucePower #STEMSupport the show

Send us Fan MailWhat if one of the most intriguing Alzheimer's interventions isn't a drug…but light?Light has long been recognized as essential for vision, sleep, and circadian rhythms - but could certain wavelengths of light actually influence the biology of the brain itself?Recent research into photobiomodulation is exploring whether carefully delivered near-infrared and red light can improve mitochondrial function, reduce neuroinflammation, enhance blood flow, and potentially slow aspects of cognitive decline.A newly published pilot study in the Journal of Alzheimer's Disease ( https://www.vielight.com/wp-content/uploads/2026/06/Vielight-University-of-Toronto-MCI-Publication.pdf ) reported improvements in memory and cognition among individuals with mild cognitive impairment following six weeks of non-invasive light therapy. While the findings are early, they raise fascinating questions about whether non-drug technologies could someday complement traditional Alzheimer's treatments.Today we're joined by two guests approaching this challenge from different perspectives.Dr. Neda Rashidi-Ranjbar, MD, Ph.D. ( https://scholar.google.com/citations?user=4y5SuLYAAAAJ&hl=en) is a physician-scientist, neuroscientist, and clinical research leader at Unity Health Toronto - St. Michael's Hospital ( https://unityhealth.to/locations/st-michaels-hospital/ ), where she leads a major neurodegenerative disease research program focused on mild cognitive impairment and Alzheimer's disease. Her work spans clinical trials, biomarkers, neuroimaging, cognitive testing, and translational neuroscience, helping bridge discoveries from the laboratory into patient care.Joining her is Peter Adams, Vice President of Business Development at VieLight ( https://www.vielight.com/ ), who has spent decades commercializing innovative healthcare technologies following leadership roles with Intel, MaRS Discovery District, and numerous international technology companies. His work focuses on bringing photobiomodulation technologies from research into real-world clinical use.Together we'll discuss the emerging science behind photobiomodulation, what we know about using light to influence brain function, how this research fits alongside today's rapidly evolving Alzheimer's therapies, and what the next generation of clinical trials will need to demonstrate as this approach becomes part of mainstream neurological care.#Alzheimers #BrainHealth #DementiaResearch #Neuroscience #Photobiomodulation #LightTherapy #MemoryLoss #CognitiveHealth #AgingBrain #MCI #Neurotechnology #MedicalInnovation #BrainScience #HealthyAging #MedicalResearch #Longevity #Biotech #NeurodegenerationSupport the show

Send us Fan MailFor decades, getting to space has largely meant one thing: launching vertically atop massive rockets from fixed launch pads. But what if the future of space access also includes aircraft capable of flying at more than twice the speed of sound, launching payloads from the edge of the atmosphere, and providing researchers with affordable access to hypersonic flight and microgravity?Joining us today is Tim Franta, Chief Executive Officer of Starfighters Space ( https://starfightersspace.com/ ), an aerospace company operating the world's only commercial fleet of flight-ready Mach 2+ F-104 Starfighters. Based at NASA's Kennedy Space Center, the company is building capabilities that span hypersonic flight testing, airborne research, astronaut and pilot training, and an ambitious air-launch platform known as STARLAUNCH, designed to provide more flexible and responsive access to space.Tim brings an unusual blend of aerospace leadership, public policy, infrastructure development, and strategic finance. Before leading Starfighters Space, he helped shape Florida's modern space ecosystem through leadership roles with Energy Florida and the Florida Space Authority, where he worked on launch infrastructure, legislation, and hundreds of millions of dollars in space-related investment.Today we'll discuss why aircraft may become an increasingly important part of the space economy, how commercial innovation is changing access to orbit, the growing importance of hypersonic technologies, and what the next decade of aerospace infrastructure might look like.#SpaceExploration #CommercialSpace #Aerospace #SpaceTechnology #SpaceInnovation #FutureOfSpace #NASA #Hypersonics #AirLaunch #SatelliteLaunch #ResponsiveSpace #NationalSecurity #DefenseTechnology #RocketScience #SpaceEconomy #NewSpace #AviationTechnology #SupersonicFlight #Mach2 #F104Starfighter #StarfightersSpace #STARLAUNCH #FutureTechnology #Innovation #Engineering #ScienceAndTechnology #ProgressPotentialAndPossibilitiesSupport the show

Send us Fan MailToday on Progress, Potential and Possibilities, we're exploring one of the most fundamental challenges facing human performance: heat. Whether it's soldiers operating in desert environments, firefighters battling infernos, police officers wearing heavy body armor, construction crews working under extreme summer temperatures, or elite athletes pushing the limits of endurance, excess heat is more than an inconvenience - it can become a life-threatening limitation.Joining us is Justin Li, Co-Founder and CEO of Qore Performance ( https://www.qoreperformance.com/ ), a Tennessee-based company pioneering a new generation of personal thermoregulation technologies. Drawing on his background as a Deputy Sheriff with the San Diego County Sheriff's Office, Justin founded Qore Performance to solve a problem he experienced firsthand - how to keep people cool, hydrated, and performing at their best in the harshest environments imaginable.Under Justin's leadership, Qore Performance has developed patented innovations including the ICEPLATE® and ICEFLASK®, systems that transform the water people already carry into wearable thermal batteries capable of cooling the body while simultaneously providing hydration. Today, Qore's American-made technologies are trusted by military personnel, law enforcement officers, first responders, industrial workers, outdoor professionals, and high-performance athletes across the country.Justin's work brings together physics, engineering, physiology, materials science, and product innovation to rethink how we manage one of the oldest biological challenges facing humanity. We discuss the science of heat transfer, the future of wearable cooling technology, entrepreneurship, and how better thermoregulation may become one of the next great frontiers in human performance.#JustinLi #QorePerformance #Thermoregulation #HeatStress #HumanPerformance #CoolingTechnology #WearableTech #Thermodynamics #Science #Innovation #Engineering #MilitaryTechnology #FirstResponders #OutdoorWorkers #OccupationalSafety #Hydration #ClimateTechnology #HealthTechnology #STEM #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailWe spend billions of dollars developing drugs to fight cancer - but what if one of the most powerful therapies begins before treatment even starts? Today we're exploring the rapidly growing field of cancer rehabilitation and the science showing that exercise, nutrition, and personalized recovery plans can dramatically improve life before, during, and after cancer.Today's first guest is Dr. Jessica Cheng, MD ( https://www.cityofhope.org/patients/find-a-doctor/jessica-cheng ) one of the country's very few fellowship-trained physicians specializing in cancer rehabilitation medicine, and currently the only fellowship-trained cancer rehabilitation specialist serving Orange County at City of Hope.Dr. Cheng is a board-certified physiatrist whose work focuses on helping cancer patients maximize their strength, mobility, independence and quality of life before, during and after treatment. Her approach combines exercise medicine, physical rehabilitation, pain management, neurological recovery and supportive care into individualized treatment plans designed to remove barriers to successful cancer therapy.After earning her medical degree from Boston University, Dr. Cheng completed residency training at Loma Linda University Health before pursuing one of the nation's premier fellowships in cancer rehabilitation at MD Anderson Cancer Center. Today she is helping shape the future of this emerging field through clinical care, research and physician education.Our second guest is cancer survivor Sharyn Araki.Sharyn's journey encompasses every stage of breast cancer - from discovering a lump and receiving a life-changing diagnosis, through chemotherapy, surgery, radiation therapy and rehabilitation. Throughout that experience she discovered that recovery wasn't simply about surviving cancer - it was about reclaiming her life.Working alongside Dr. Cheng, Sharyn embraced structured exercise and rehabilitation - including an unexpected passion for pickleball - which helped combat debilitating fatigue, rebuild strength and restore confidence. ( https://www.cityofhope.org/orange-county/talking-hope/physical-medicine-and-rehabilitation )Perhaps most remarkably, Sharyn navigated this entire journey while raising seven children, offering a powerful perspective on resilience, family, faith and what it truly means to recover after cancer treatment.#CancerRehabilitation #CancerSurvivor #BreastCancer #CancerRecovery #ExerciseIsMedicine #Prehabilitation #CancerCare #Oncology #IntegrativeOncology #CancerResearch #Fitness #HealthInnovation #QualityOfLife #Stem #MedicalScience #PhysicalTherapy #Wellness #CancerFatigue #CityOfHope #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailFor decades, the war on cancer has focused on destroying cancer cells directly - with chemotherapy, radiation, and targeted drugs. But what if the future of cancer treatment is not about attacking cancer ourselves...but teaching our own immune system to do it for us?Today we're exploring a new generation of immunotherapies designed to turn the body's own defenses into a precision weapon against cancer.Over the past decade, immunotherapies such as checkpoint inhibitors and CAR-T cell therapies have transformed the treatment landscape for many cancers. But major challenges remain - including limited response rates, treatment resistance, toxicity, and the enormous complexity and cost of manufacturing many next-generation therapies.Our guest today believes the next breakthrough may come from a new generation of personalized immunotherapies designed to activate a patient's own immune system against their cancer - while also being manufactured as an accessible, off-the-shelf treatment.Joining us is Dr. William Williams, MD - President and CEO of BriaCell Therapeutics ( https://briacell.com/ ).Dr. Williams brings more than 35 years of experience spanning academia and the biopharmaceutical industry. He has helped advance numerous medicines from discovery through clinical development, including work contributing to therapies such as Jakafi and Olumiant during his time at Incyte, and multiple oncology programs during his career at GlaxoSmithKline.Before entering industry leadership, Dr. Williams was a researcher at the University of Pennsylvania focused on molecular immunology, receptor biology, and early DNA vaccine approaches.Today we'll discuss the evolution of cancer immunotherapy, BriaCell's Bria-IMT platform, the challenges of treating advanced breast cancer, and whether the future of oncology lies in creating therapies that can truly mobilize each patient's own immune system.#CancerResearch #CancerImmunotherapy #Immunotherapy #CancerTreatment #Oncology #PrecisionMedicine #PersonalizedMedicine #Biotechnology #Biotech #LifeSciences #DrugDiscovery #ClinicalTrials #BreastCancer #MetastaticBreastCancer #CancerVaccine #CellTherapy #TumorImmunology #TCells #ImmuneSystem #MedicalInnovation #FutureOfMedicine #HealthcareInnovation #BiomedicalResearch #Pharma #PharmaceuticalInnovation #SciencePodcast #ProgressPotentialAndPossibilities #PPPShowSupport the show

Send us Fan MailWe tend to think of menopause as a personal health issue - but in the workplace it quietly shows up as one of the largest unmodeled productivity shifts in the modern economy.Recent data from the Korn Ferry Institute, in collaboration with Vira Health, suggests nearly half of women report that perimenopause or menopause symptoms impact their work performance. And research cited by the Mayo Clinic estimates menopause-related productivity loss in the U.S. alone at roughly $1.8 billion annually.So the question becomes: what happens when a normal biological transition starts to meaningfully affect workforce participation, retention, and productivity?Karen Bishop, MS is Senior Director of HR Rewards at Astellas Pharma US ( https://www.astellas.com/en ), where she leads global benefits, compensation strategy, and employee well-being programs.Across more than two decades in HR leadership roles at organizations including MilliporeSigma, Shire (now Takeda), Cabot Corporation, and Putnam Investments, Karen has built deep expertise in total rewards strategy, healthcare benefits design, retirement systems, and organizational change.At Astellas, Karen has helped evolve an internal menopause workplace pledge into a broader global initiative focused on manager education, employee support systems, and benefits navigation - positioning menopause as part of a larger conversation around workforce health, retention, and productivity.#menopause #workplacewellbeing #hrleadership #futureofwork #corporatestrategy #workforceanalytics #womenshealth #hrtech #talentmanagement #employeeexperience #healthcareeconomics #productivity #leadershipdevelopment #totalrewards #organizationaldesign #publichealth #biologicalaging #genderequity #workplaceculture #healthpolicySupport the show

Send us Fan MailEvery cup of coffee, every chocolate bar, every loaf of bread has a hidden ingredient you probably never think about: water. But as climate change reshapes where and how we grow food, water is becoming one of the biggest risks facing our global supply chains.We often talk about climate change through the lens of rising temperatures, extreme weather, or carbon emissions — but behind many of these challenges is a resource that determines whether societies can thrive: freshwater.Agriculture accounts for roughly 70% of global freshwater withdrawals, and the systems that produce, transport, and distribute our food depend on reliable access to water. But climate volatility, changing precipitation patterns, drought, and disruptions in global trade are creating new risks throughout the agricultural supply chain.Our guest today is helping organizations understand and address these challenges.Paul Reig is the Founder and CEO of Bluerisk ( https://blueriskintel.com/ ), a company focused on helping businesses identify, assess, and manage water-related risks. Paul brings nearly two decades of experience working at the intersection of water science, corporate strategy, and sustainability.Before founding Bluerisk, Paul spent nine years at the World Resources Institute, where he led the development of the Aqueduct Water Risk Atlas - one of the world's leading tools for understanding global water risks - and helped create frameworks for measuring corporate water stewardship.Paul has advised more than 40 major global companies on how to assess water risks, establish resilience strategies, and develop solutions that protect shared water resources.Today we'll discuss why water may become one of the defining challenges of the 21st century, how disruptions in agriculture and trade can amplify water stress, and what companies, governments, and innovators can do to build a more water-resilient future.#WaterRisk #WaterCrisis #ClimateChange #ClimateAdaptation #WaterSecurity #FoodSecurity #SustainableAgriculture #AgricultureTechnology #FutureOfFood #SupplyChainResilience #CorporateSustainability #EnvironmentalScience #ClimateInnovation #RegenerativeAgriculture #PrecisionAgriculture #WaterStewardship #GlobalWaterCrisis #ClimateTech #Sustainability #EarthScience #FoodSystems #Agritech #Innovation #ScienceAndTechnology #ProgressPotentialAndPossibilitiesSupport the show

Send us Fan MailWe usually think of health ministers as politicians. Dr. Evis Sala, MD, PhD is something entirely different. She's one of the world's leading cancer imaging researchers who helped pioneer AI in radiology - and now she's responsible for the healthcare of an entire nation. What happens when a scientist takes the helm of public health?Our guest today is one of the world's leading physician-scientists in medical imaging who has recently taken on one of the biggest leadership challenges in healthcare.Dr. Evis Sala, MD, PhD ( https://www.kryeministria.al/en/ministrat/evis-sala/ ) currently serves as the Minister of Health and Social Protection of Albania  ( https://shendetesia.gov.al/en/hap/ ). Before entering government, Dr. Sala built an extraordinary international career spanning the University of Cambridge, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and Rome's Policlinico Gemelli, while becoming internationally recognized for her pioneering work in advanced cancer imaging, precision diagnostics, women's cancers, and the integration of artificial intelligence into radiology.Holding both an MD from the University of Tirana and a PhD in Epidemiology from the University of Cambridge, Dr. Sala has spent decades helping shape how we detect, diagnose, and ultimately treat cancer. Today, she is applying that scientific rigor and international experience to improving the health of an entire nation.#EvisSala #Healthcare #PublicHealth #Medicine #ArtificialIntelligence #AI #Radiology #CancerResearch #PrecisionMedicine #CancerImaging #MedicalInnovation #DigitalHealth #HealthPolicy #Oncology #MRI #FutureOfMedicine #HealthcareInnovation #MedicalTechnology #SciencePodcast #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailImagine a world where a child with a rare disease in a rural hospital could benefit from the collective intelligence of 500 of the world's best children's hospitals - not years later, but in real time. What if artificial intelligence could connect medical expertise globally while keeping every patient's data private? That is the ambitious vision behind the Pediatric Moonshot ( https://pediatricmoonshot.org/ ).Our guest today has spent more than four decades at the forefront of nearly every major transformation in enterprise computing. Dr. Timothy Chou earned his Ph.D. in Electrical Engineering from the University of Illinois before beginning his career at Tandem Computers, one of Silicon Valley's pioneering companies in fault-tolerant distributed computing. He later served as President of Oracle On Demand, helping lead Oracle's early cloud computing initiatives years before "the cloud" became part of everyday vocabulary.Alongside his industry career, Dr. Chou has taught at Stanford University since 1982, where he created the university's first course on cloud computing and has inspired generations of entrepreneurs and technology leaders. Today he serves on the Board of Directors of Teradata, chairs the IoT initiative at Alchemist Accelerator, advises emerging enterprise software companies, and was recognized as one of the National Association of Corporate Directors' Directorship 100 honorees.But after what many would consider a complete career, Dr. Chou came out of retirement to pursue perhaps his most ambitious mission yet. Inspired by one of his Stanford students, he founded Pediatric Moonshot, a nonprofit with a bold vision: to reduce healthcare inequity by enabling privacy-preserving artificial intelligence to securely learn from the more than one million medical machines spread across roughly 500 children's hospitals around the world - without requiring patient data to leave those hospitals.Today we're going to explore not only the future of pediatric healthcare and artificial intelligence, but also whether medicine is on the verge of its own Internet moment - where distributed intelligence, rather than centralized data, could fundamentally reshape how care is delivered around the world.#PediatricMoonshot #ArtificialIntelligence #AIHealthcare #HealthcareInnovation #FutureOfMedicine #DigitalHealth #HealthTech #MedicalAI #AIRevolution #EdgeComputing #CloudComputing #FederatedLearning #RareDisease #Pediatrics #ChildrenHealthcare #PrecisionMedicine #HealthcareEquity #Innovation #Technology #SiliconValley #StanfordUniversity #AIAgents #FutureTechnology #MedicineOfTheFuture #ProgressPotentialAndPossibilitiesSupport the show

Send us Fan MailFor decades, women undergoing mastectomy have largely faced the same choice: reconstruct with permanent implants or use tissue transplanted from another part of the body. But what if there was a third option - not replacing what's been lost, but actually regenerating it? Today we're exploring one of the most ambitious ideas in regenerative medicine: a 3D-bioprinted scaffold designed to help the body rebuild living tissue.Dr. Claudia Chavez-Munoz, MD, Ph.D. is an internationally recognized surgeon-scientist, regenerative medicine innovator, and Chief Scientific Officer and co-founder of Conexeu Sciences ( https://www.conexeu.com/ ). With a career spanning plastic surgery, wound healing, tissue engineering, and extracellular matrix biology, she has dedicated more than two decades to understanding how the body repairs itself - and how that knowledge can be translated into next-generation therapies.Dr. Chavez-Munoz earned her MD from the Universidad Nacional Autónoma de México, completed her Ph.D. in Plastic Surgery at the University of British Columbia, and pursued postdoctoral training in tissue engineering and reconstructive surgery at Northwestern University Feinberg School of Medicine. Her pioneering work has ranged from stem cell biology and skin regeneration to biomaterials and organ reseeding technologies. Throughout her academic career at the University of British Columbia and Vancouver General Hospital, she has mentored future physician-scientists while advancing innovative approaches to tissue regeneration.Today, she leads the scientific development of Conexeu's "10 Minute Tissue™" platform and is spearheading what may become the world's first 3D-bioprinted regenerative breast - a temporary scaffold designed to disappear over time as a patient's own tissue regenerates and replaces it. Her work represents a bold vision for the future of reconstructive surgery: moving beyond permanent implants and toward living, regenerative solutions that harness the body's natural healing capacity.#BreastCancer #BreastReconstruction #RegenerativeMedicine #3DBioprinting #TissueEngineering #Bioprinting #PlasticSurgery #Biotechnology #StemCells #WoundHealing #Biomaterials #PrecisionMedicine #FutureOfMedicine #HealthcareInnovation #MedicalInnovation #ExtracellularMatrix #CancerSurvivorship #Surgery #WomenInSTEM #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailWhat if radiation could become one of the most precise medicines ever invented? Long before radiopharmaceuticals became one of the hottest areas in biotech, today's guest was helping pioneer targeted radiation therapies that seek out cancer cells while minimizing damage to healthy tissue. Today, the field is attracting billions in investment and reshaping oncology.Our guest today is one of the true pioneers of modern targeted radiopharmaceutical therapy.Dr. Ebrahim Delpassand, MD is the Founder, Chairman and CEO of RadioMedix ( https://radiomedix.com/ ), a clinical-stage biotechnology company developing next-generation targeted radioactive diagnostics and therapeutics for cancer.Long before radiopharmaceuticals became one of the most exciting areas in precision oncology, Dr. Delpassand was introducing these therapies to patients who had exhausted every other option. As former Deputy Chairman and Chief of Clinical Nuclear Medicine at MD Anderson Cancer Center, Dr. Delpassand served as Principal Investigator on some of the very first FDA Investigational New Drug programs for Lutetium-177 therapies in the United States, including the nation's first INDs for Lu-177 DOTATATE peptide receptor radionuclide therapy and Lu-177 PSMA-617 therapy.Board-certified in Nuclear Medicine and trained in both pathology and nuclear medicine at Baylor College of Medicine, Dr. Delpassand has authored more than ninety peer-reviewed publications and has spent decades advancing therapeutic nuclear medicine through research, clinical care, and education.But perhaps even more remarkable is his entrepreneurial journey. Nearly twenty years ago, convinced that targeted radiopharmaceuticals represented a fundamentally new way to fight cancer, Dr. Delpassand founded RadioMedix and personally sustained the company through its earliest years while helping build not only innovative therapies, but also isotope production capabilities, cGMP manufacturing infrastructure, and broader access to these life-saving treatments.Today, as radiotheranostics transforms cancer care around the world, Dr. Delpassand joins us to discuss where the field began, where it is heading, and what the next generation of precision radiation medicines could mean for patients.#Radiopharmaceuticals #CancerResearch #CancerTherapy #PrecisionMedicine #Oncology #Radiotheranostics #NuclearMedicine #Biotechnology #Biotech #MedicalInnovation #HealthcareInnovation #TargetedTherapy #AlphaTherapy #Lutetium177 #PrecisionOncology #FutureOfMedicine #CancerTreatment #DrugDevelopment #SciencePodcast #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailCan artificial intelligence really think like a physician - or is it simply predicting words?This week we're joined by Dr. Michal Tzuchman-Katz, MD, physician, AI entrepreneur, pediatrician, and Chief Innovation & Research Officer at Maccabi Healthcare, one of the world's most advanced healthcare organizations. We explore why the future of medicine isn't just better AI - it's building healthcare systems that learn from every patient.Dr. Michal Tzuchman-Katz, MD is a physician, technologist, entrepreneur, and healthcare innovation leader who currently serves as Chief Innovation & Research Officer at Maccabi Healthcare Services ( https://www.maccabi4u.co.il/ ), one of Israel's largest and most advanced healthcare organizations.What makes Dr. Tzuchman-Katz's story extraordinary is that she has worked across nearly every layer of modern health technology. She began her career as a software engineer, earned her medical degree with honors, trained as a pediatrician, studied genomics and biomedical informatics, and went on to co-found and lead Kahun, an AI-powered clinical reasoning company that developed a knowledge-graph engine containing more than 30 million evidence-based medical insights.At Kahun, Dr. Tzuchman-Katz became a pioneer in explainable AI for physicians, focusing on making AI-generated recommendations transparent, traceable to medical evidence, and aligned with the way clinicians actually think. Today, at Maccabi, Dr. Tzuchman-Katz oversees innovation and research initiatives that leverage one of the world's richest longitudinal healthcare datasets and biobanks to develop and scale technologies that can improve patient outcomes at population level.Remarkably, while leading innovation for a major healthcare system, Dr. Tzuchman-Katz continues to practice as a pediatrician, giving her a uniquely grounded perspective on the promises and limitations of AI in real clinical care.#HealthcareInnovation #ArtificialIntelligence #MedicalAI #PrecisionMedicine #HealthTech #DigitalHealth #ClinicalAI #Medicine #Healthcare #Biotech #Genomics #Innovation #FutureOfMedicine #HealthcareData #MachineLearning #MedicalResearch #Pediatrics #PreventiveMedicine #PersonalizedMedicine #PPPSupport the show

Send us Fan MailFor decades we've treated autoimmune diseases by suppressing the immune system - but what if we've been approaching the problem all wrong? What if, instead of lifelong immunosuppression, we could selectively eliminate the immune cells causing disease and allow the immune system to rebuild itself? Today we're exploring one of the hottest areas in biotechnology: T-cell engagers and the possibility of an "immune reset."Dr. Jeffrey Jones, MD, MPH is Chief Medical Officer of Cullinan Therapeutics ( https://cullinantherapeutics.com/ ) and one of the leaders helping bring the power of T-cell engager therapies beyond cancer and into autoimmune disease. With more than two decades of experience spanning academia and industry, Dr. Jones has been at the forefront of clinical development in hematology, oncology, and immunology.Prior to joining Cullinan, Dr. Jones served as Vice President of Global Drug Development at Bristol Myers Squibb, leading programs in lymphoma and myeloid diseases and helping guide the lifecycle strategy for Reblozyl®. Earlier, he held leadership positions at Celgene, where he developed clinical strategies across lymphoma and chronic lymphocytic leukemia portfolios.Before entering industry, Dr. Jones spent more than a decade at The Ohio State University, where he led the Chronic Lymphocytic Leukemia clinical research program and served as Associate Professor of Internal Medicine. Today, he is helping pioneer a new generation of T-cell engagers designed not to continuously suppress the immune system, but potentially to reset it - opening the possibility of durable, treatment-free remission for diseases such as rheumatoid arthritis, lupus, lupus nephritis, and autoimmune cytopenias.Dr. Jones earned his MD from the University of Michigan Medical School, an MPH from the University of Texas School of Public Health, and an MBA from The Ohio State University Fisher College of Business.#AutoimmuneDisease #Lupus #RheumatoidArthritis #Immunology #TCellEngagers #Biotechnology #DrugDevelopment #PrecisionMedicine #ImmuneSystem #ImmuneReset #ClinicalTrials #Biotech #HealthcareInnovation #FutureOfMedicine #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailFor decades, fusion researchers were chasing a single goal: ignition. But what if ignition isn't the finish line? What if it's only the starting gun? Today we're joined by Dr. Will Regan, Founder and Chief Scientist of Pacific Fusion, a company betting that the future of fusion won't be won by building bigger machines - but by solving one of engineering's toughest manufacturing challenges.Dr. Will Regan, Ph.D. is the Founder and Chief Scientist of Pacific Fusion ( https://www.pacificfusion.com/ ), where he is helping lead one of the most ambitious efforts in advanced inertial fusion energy: developing a practical, scalable pathway to commercial fusion power using pulsed power systems and high-yield target physics.Before founding Pacific Fusion, Will served as a Project Lead and Rapid Evaluator at X, the moonshot factory, where he helped originate and develop breakthrough concepts in agricultural and systems innovation, including early foundational work behind the Mineral initiative focused on sustainable food production at planetary scale.Earlier in his career, he was an ARPA-E Fellow at Advanced Research Projects Agency–Energy, where he worked at the intersection of high-risk, high-reward energy technologies and national-scale innovation programs—an experience that helped shape his approach to large-scale energy system design and technology acceleration.Will earned his PhD in Physics from University of California, Berkeley, following his undergraduate degree in Physics from Cornell University. Across academia, government, and moonshot industry environments, he has consistently focused on translating frontier physics into real-world systems—now centered on one of the most consequential engineering challenges of the century: fusion energy.At Pacific Fusion, he is working to turn high-gain fusion concepts into repeatable, engineered systems that could fundamentally reshape global energy infrastructure.#FusionEnergy #NuclearFusion #PacificFusion #WillRegan #CleanEnergy #FutureOfEnergy #FusionPower #InertialConfinementFusion #ICF #MagLIF #SandiaLabs #LawrenceLivermore #NIF #AdvancedEnergy #EnergyInnovation #Physics #Engineering #ClimateTech #MoonshotFactory #ARPAE #SciencePodcast #TechnologyPodcast #ProgressPotentialPossibilities #STEM #DeepTechSupport the show

Send us Fan MailEveryone talks about getting humans to Mars. But almost nobody talks about the harder question - how do you keep them alive once they get there? My guest today says the answer isn't bigger rockets - it's plants.Mark Ciotola is CEO and Co-Founder of Sustain Space ( https://www.sustainspace.com/ ), a company focused on developing regenerative life-support technologies for future space missions while translating those innovations to improve agriculture and sustainability on Earth. Through Sustain Space's Orbital Genomics initiative, he is helping advance research into growing plants in space environments - an essential capability for long-duration missions to the Moon, Mars, and beyond.Mark's career spans entrepreneurship, academia, industry, and government, including work with NASA, Genentech, Applied Biosystems, Intuit, Carnegie Mellon University, Monash University, San Francisco State University, and Singularity University, where he served as Entrepreneur-in-Residence and faculty member in Space and Physical Sciences.A physicist, entrepreneur, educator, and sustainability advocate, Mark is particularly interested in regenerative ecosystems, closed-loop life-support systems, space agriculture, and the broader question of how humanity can build a sustainable future both on Earth and beyond it.Important Episode Link - HudsonAlpha Institute for Biotechnology -https://www.hudsonalpha.org/#MarkCiotola #SustainSpace #SpaceAgriculture #SpaceFarming #MarsColonization #MoonBase #NASA #SpaceBiology #Astrobiology #PlantScience #OrbitalGenomics #ControlledEnvironmentAgriculture #VerticalFarming #Hydroponics #SyntheticBiology #FutureOfFood #SpaceTechnology #SpaceExploration #LifeSupportSystems #ClosedLoopSystems #MarsMission #MoonMission #Humanity #Innovation #SciencePodcast #STEM #FutureOfHumanity #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailWe often assume confusion after surgery is temporary. But what if those few days of delirium are actually a major turning point in the aging brain? New research from Harvard and Hebrew SeniorLife suggests postoperative delirium may be the strongest predictor of long-term cognitive decline - and what we're learning could fundamentally change how we think about dementia and healthy aging.Each year, millions of older adults undergo surgery successfully, only to experience episodes of confusion, disorientation, memory impairment, or altered awareness in the days that follow. For decades, many clinicians viewed postoperative delirium as a temporary complication that resolved once patients left the hospital.But emerging research suggests a much more profound story.Our guest today is Dr. Tammy Hshieh, MD, MPH, is physician-scientist, geriatrician, and internationally recognized expert on delirium, cognitive impairment, and healthy aging. Dr. Hshieh serves as Assistant Scientist at the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife ( https://www.marcusinstituteforaging.org/who-we-are/profiles/tammy-hshieh-md-mph ), Assistant Professor of Medicine at Harvard Medical School ( https://connects.catalyst.harvard.edu/Profiles/display/Person/33333 ), and Associate Physician at Brigham and Women's Hospital ( https://physiciandirectory.brighamandwomens.org/Details/12170 ).After earning her undergraduate degree in Biochemistry from Harvard University and her MD from Brown University's Alpert Medical School, Dr. Hshieh completed residency training in Internal Medicine at Beth Israel Deaconess Medical Center, a fellowship in Geriatric Medicine through Harvard Medical School, and earned a Master of Public Health from the Harvard T.H. Chan School of Public Health.Dr. Hshieh's research focuses on understanding, preventing, and treating delirium and cognitive decline in older adults - conditions that carry enormous consequences for independence, quality of life, and healthcare systems worldwide.In groundbreaking work recently published in JAMA Internal Medicine, Dr. Hshieh and colleagues demonstrated that postoperative delirium remains the strongest predictor of long-term cognitive decline, even after accounting for rehospitalizations and other markers of illness and frailty. Their findings suggest that delirium may represent far more than a transient hospital complication - it may be a critical turning point in the trajectory of brain aging itself.Clinically, Dr. Hshieh co-manages older surgical patients at Brigham and Women's Hospital in one of the nation's most innovative geriatric-surgical care programs and leads the Older Adult Hematologic Malignancy Clinic at Dana-Farber Cancer Institute ( https://www.dana-farber.org/find-a-doctor/tammy-t-hshieh ), where she works to improve outcomes for older adults facing cancer treatment.Today we'll discuss delirium, dementia, cognitive resilience, surgical risk, brain aging, and what patients, families, and healthcare systems can do to better protect the aging brain.#Delirium #Dementia #BrainHealth #HealthyAging #CognitiveDecline #Alzheimers #HarvardMedicine #Geriatrics #Longevity #Surgery #PostoperativeDelirium #AgingResearch #Neuroscience #Healthcare #Medicine #BrainAging #CognitiveHealth #Prevention #Podcast #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailWhat if a device small enough to fit in your pocket could detect a potentially fatal heart rhythm before symptoms even appear? My guest today helped make that possible. Dr. David Albert, MD - Founder of AliveCor, pioneered smartphone ECG technology and transformed how millions of people monitor their hearts.Dr. David Albert, MD is a physician, inventor, and serial entrepreneur whose career has helped define the modern era of digital cardiology and personal health technology. A graduate of Harvard College and Duke University School of Medicine, Dr. Albert has spent more than four decades translating breakthrough ideas into life-saving products. He founded Corazonix in the 1980s, Data Critical in the 1990s - which later became part of GE Healthcare - and ultimately served as Chief Scientist and Chief Clinical Scientist for GE Cardiology before returning to entrepreneurship.In 2010, Dr. Albert founded AliveCor ( https://alivecor.com/ ), pioneering the smartphone-based ECG and helping launch one of the earliest and most clinically validated digital health platforms. AliveCor's KardiaMobile technology transformed cardiac monitoring by placing medical-grade electrocardiograms in the hands of millions of consumers and patients worldwide. Beyond AliveCor, Dr. Albert founded InnovAlarm and Lifetone Technology, developing innovations that improve home safety and emergency alerting. An inventor with more than 80 U.S. patents and over 100 scientific publications, Dr. Albert has devoted his career to democratizing healthcare technology and empowering people to better understand - and protect - their own health.#DavidAlbert #AliveCor #KardiaMobile #DigitalHealth #Cardiology #HeartHealth #ECG #AtrialFibrillation #WearableTech #HealthcareInnovation #MedTech #RemoteMonitoring #AIinHealthcare #PrecisionMedicine #PreventiveMedicine #Entrepreneurship #HealthcareTechnology #GEHealthcare #MedicalDevices #FutureOfMedicine #DigitalBiomarkers #HealthTech #Inventor #StartupFounder #Cardiologist #PatientEmpowerment #HeartDisease #MedicalInnovation #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailFor decades, scientists have searched for better cancer drugs. But what if the biggest challenge isn't discovering the drug - it's getting it to the tumor? My guest today is developing programmable viruses designed to travel throughout the body, selectively amplify inside metastatic lesions, and transform tumors into factories for their own destruction.Dr. Eric Poma, Ph.D. is Chief Executive Officer of Calidi Biotherapeutics ( https://www.calidibio.com/ ), a biotechnology company developing targeted genetic medicines designed to deliver therapeutic payloads directly to tumors throughout the body.Dr. Poma brings more than three decades of experience across biotechnology, oncology drug development, business development, and capital markets. Prior to joining Calidi in 2025, he served as CEO of Molecular Templates, where he helped raise more than $250 million in equity financing and secured strategic partnerships with companies including Takeda, Vertex, and Bristol Myers Squibb.Earlier in his career, Dr. Poma held leadership roles at ImClone Systems during the rise of targeted cancer therapies, served as Vice President of Business Development at Innovive Pharmaceuticals, and worked as a healthcare and biotechnology analyst. He holds a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill and an MBA from NYU's Stern School of Business.Today we will discuss one of the most difficult challenges in oncology - how to successfully deliver powerful therapies to metastatic tumors throughout the body - and how Calidi's RedTail platform aims to use engineered oncolytic viruses as targeted delivery vehicles capable of reaching cancer cells, modifying the tumor microenvironment, and potentially enabling a new generation of genetic medicines.#CancerResearch #Oncology #Immunotherapy #GeneTherapy #Biotechnology #CancerTreatment #PrecisionMedicine #OncolyticVirus #CancerScience #BiotechInnovation #MetastaticCancer #IL15 #VacciniaVirus #GeneticMedicine #SyntheticBiology #TumorMicroenvironment #FutureOfMedicine #DrugDelivery #Biopharma #EricPoma #CalidiBiotherapeutics #CancerBreakthrough #MedicalInnovation #LifeSciences #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailFor decades, oncologists have had to wait until cancer became visible on a scan before knowing whether it had returned. But what if doctors could detect microscopic traces of cancer months earlier with a simple blood draw - and use that information to decide who actually needs treatment? Today we're exploring a breakthrough that may fundamentally change the way cancer is monitored and treated.Eric Matthews is General Manager of Biopharma at Natera ( https://www.natera.com/ ), a leader in personalized molecular diagnostics and the company behind Signatera, the first FDA-approved molecular residual disease companion diagnostic.Over the past 25 years, Eric has helped bring nine medicines to market across nineteen indication launches, building a career at the forefront of oncology, precision medicine, and biopharmaceutical innovation.Before joining Natera, Eric served as Chief Business Officer at Caris Life Sciences, where he focused on diagnostic, data, and drug discovery partnerships. Prior to that, he was Chief Commercial Officer at Arcus Biosciences, helping forge major strategic collaborations including Arcus' landmark partnership with Gilead Sciences.Eric's previous leadership roles include Vice President of Global Marketing for Immuno-Oncology at AstraZeneca and commercial leadership positions at Genentech and Roche, where he worked on some of the most influential cancer therapies of the modern era, including Avastin and Tecentriq.Eric holds an MBA in Health Sector Management, a Master's in Health Policy and Economics, and dual bachelor's degrees in Molecular Biology and Economics from Duke University.Today we discuss the future of molecular residual disease testing, how personalized blood-based diagnostics are changing cancer care, the recent FDA approval of Signatera as the first MRD companion diagnostic, and what the next decade may hold for truly individualized oncology.#CancerResearch #CancerDetection #PrecisionMedicine #Oncology #LiquidBiopsy #Signatera #Natera #CancerCare #Biotech #HealthcareInnovation #Immunotherapy #Tecentriq #BladderCancer #MolecularBiology #PersonalizedMedicine #CancerTreatment #MedicalInnovation #FutureOfMedicine #Biotechnology #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailFor decades, medicine has recognized that pregnancy and menopause transform nearly every system in the body. Yet only recently have researchers begun asking a simple question: what happens to chronic skin diseases like eczema and psoriasis during these major biological transitions? The answers may reveal one of the biggest blind spots in modern medicine.Dr. Doral Fredericks, PharmD, MBA is Vice President and Head of Global Medical Affairs and Outcomes Research at Organon ( https://www.organon.com/ ), a global healthcare company focused on improving women's health throughout every stage of life.With nearly three decades of experience spanning clinical pharmacy, pharmaceutical development, medical affairs, and healthcare strategy, Dr. Fredericks has held senior leadership roles across some of the world's leading healthcare organizations, including Organon, Dermavant Sciences, ACADIA Pharmaceuticals, Bausch + Lomb, Novartis, AstraZeneca, and Kaiser Permanente.Throughout her career, Dr. Fredericks has led global medical affairs organizations, overseen clinical development programs, real-world evidence generation, physician education initiatives, and outcomes research efforts across multiple therapeutic areas. Her work has focused on translating scientific innovation into meaningful improvements in patient care while helping healthcare systems better understand the unique needs of diverse patient populations.Today, Dr. Fredericks is helping drive a growing conversation around female dermatology - a field examining how major biological transitions such as pregnancy, postpartum recovery, perimenopause, and menopause can profoundly influence chronic skin diseases including eczema, psoriasis, and other inflammatory conditions.On this episode, we'll explore why women's skin health remains an underrecognized area of medicine, how hormonal and immune changes across a woman's lifespan affect dermatologic disease, and what the future of personalized care may look like as researchers begin paying closer attention to the unique biology of female patients.#WomensHealth #Dermatology #Menopause #Psoriasis #Eczema #SkinHealth #Healthcare #PrecisionMedicine #AutoimmuneDisease #Hormones #Postpartum #PregnancyHealth #MedicalResearch #Inflammation #Medicine #Organon #Dermatologist #HealthyAging #Longevity #HealthcareInnovation #SciencePodcast #MedicalScience #FutureOfMedicine #SkinDisease #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailHe spent fifty-five years searching for answers. Dozens of doctors. Hundreds of tests. Twelve different diagnoses. And what he discovered wasn't just a problem with medicine - it was a problem with the system itself.Haresh Patel ( https://hareshpatel.ai/ ) is an entrepreneur, engineer, Founder and CEO of Sanare Health AI ( https://sanarehealth.ai/ ), and author of the memoir The Ghost in My Body: What Twelve Doctors Couldn't Find ( https://www.amazon.com/Ghost-My-Body-Doctors-Couldnt-ebook/dp/B0GL561XNC ).After immigrating from India and earning an electrical engineering degree from the University of Notre Dame, Haresh built a distinguished career in Silicon Valley, ultimately founding Mercatus, a private-markets data platform that grew to manage more than $1.5 trillion in assets before being acquired by State Street in 2021.But behind that business success was a deeply personal story. For more than 55 years, Haresh lived with unexplained symptoms, navigating a maze of specialists, tests, and conflicting diagnoses without ever receiving a clear answer. Rather than accepting the limitations of the system, he applied the same systems-thinking and pattern-recognition skills that made him successful in technology and finance to his own health journey.That experience led Haresh to a provocative conclusion: many patients don't suffer from a lack of doctors - they suffer from a lack of synthesis. Modern medicine excels at specialization, but often struggles to connect information across disciplines, timelines, and life experiences.Today, Haresh is the founder of Sanare Health AI, an AI-powered diagnostic intelligence platform designed to help patients with complex, chronic, and undiagnosed conditions uncover patterns hidden within fragmented medical data. His mission is to give physicians a more complete picture of the patient, empower individuals to own their health stories, and help solve one of healthcare's most overlooked challenges: the millions of people still searching for answers.We discuss diagnostic failure, AI in medicine, data sovereignty, root-cause healthcare, and what happens when a patient spends a lifetime becoming the expert on his own condition.#HareshPatel #TheGhostInMyBody #SanareHealth #ArtificialIntelligence #AIHealthcare #RareDisease #UndiagnosedDisease #DiagnosticOdyssey #PrecisionMedicine #RootCauseMedicine #HealthcareInnovation #FutureOfMedicine #MedicalAI #HealthTech #ChronicIllness #PatientAdvocacy #Longevity #MedicalDiagnostics #ComplexPatients #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailBefore your heart, brain, or lungs fully developed, one remarkable temporary organ was making decisions that may influence your health for decades. Dr. Perrie O'Tierney-Ginn ( https://www.placentascience.com/ ) explains why the placenta could be the most important organ you've never thought about.Dr. Perrie O'Tierney-Ginn, Ph.D. is Executive Director of the Woman, Mother & Baby Research Institute at Tufts Medical Center ( https://www.tuftsmedicine.org/research-clinical-trials/research-institutes-research-specialty/woman-mother-baby-research-institute ) and a Research Associate Professor in both Obstetrics & Gynecology at Tufts University School of Medicine ( https://www.tuftsmedicine.org/research-clinical-trials/research-institutes-research-specialty/woman-mother-baby-research-institute/laboratories/otierney-ginn-laboratory ) and the Friedman School of Nutrition Science and Policy ( https://nutrition.tufts.edu/academics/faculty/perrie-otierney-ginn ).A self-described "Perinatal Ecologist," Dr. O'Tierney-Ginn studies one of the most remarkable - and often overlooked - organs in human biology: the placenta. Her research explores how a mother's nutritional status, metabolism, and environment shape placental function, influence fetal growth, and ultimately affect lifelong health outcomes.Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Dr. O'Tierney-Ginn's work focuses on understanding how nutrients are transported from mother to baby, how maternal obesity and metabolic health alter fetal development, and how the placenta acts as a sophisticated biological sensor that helps determine the earliest foundations of human health.With a Ph.D. in Cell Biology and Anatomy from Queen's University and leadership roles at Case Western Reserve University and Tufts Medical Center, Dr. O'Tierney-Ginn is helping redefine our understanding of pregnancy - not as a nine-month event, but as one of the most important developmental windows influencing health across the entire lifespan.#Placenta #Pregnancy #MaternalHealth #WomensHealth #DevelopmentalBiology #Longevity #Metabolism #Obesity #Diabetes #Nutrition #PrecisionMedicine #Epigenetics #Microbiome #SciencePodcast #Medicine #FetalDevelopment #TuftsMedicine #PublicHealth #PreventiveMedicine #FutureOfHealthSupport the show

Send us Fan MailFor decades, we've talked about the digital revolution - but according to Professor Klaus Schwab, we've already moved beyond it. We're now entering what he calls the Intelligent Age - where intelligence itself becomes the most valuable resource on Earth.Professor Klaus Schwab is Founder of the World Economic Forum and one of the most influential thinkers on how technological and societal systems evolve ( https://schwabacademy.org/klaus-schwab ).Over more than five decades, Professor Schwab helped shape global conversations around stakeholder capitalism and the Fourth Industrial Revolution - frameworks that examined how digital technologies were transforming economies and institutions.Now, in a new phase of his work, Professor Schwab has turned his focus to what he calls the “Intelligent Age” - a period defined not just by digital tools, but by the convergence of artificial intelligence, biotechnology, and quantum computing as foundational drivers of society.Through a series of recent books - including Thriving and Leading in the Intelligent Age, Longevity and Retirement in the Intelligent Age, Restoring Truth and Trust, and Universities in the Intelligent Age - he explores how intelligence itself is becoming the world's most important resource, and what that means for leadership, education, institutions, and human purpose.At the core of Professor Schwab's work is a central question:How do we ensure that as machines become more intelligent, societies become more human?Important Episode Links -Schwab Academy - https://schwabacademy.org/Schwab Foundation for Social Entrepreneurship - https://www.schwabfound.org/homeGlobal Shapers Community - https://www.globalshapers.org/homeThriving and Leading in the Intelligent Age: Mastering Change with Purpose - https://www.amazon.com/Thriving-Leading-Intelligent-Age-Mastering/dp/297019547X/ref=tmm_hrd_swatch_0Longevity and Retirement in the Intelligent Age: Opening New Horizons in Later Life - https://www.amazon.com/Longevity-Retirement-Intelligent-Age-Horizons/dp/2970198800/ref=tmm_pap_swatch_0Universities, Professors, and Students in the Intelligent Age: A Call for Systems Change - https://www.amazon.com/Universities-Professors-Students-Intelligent-Age/dp/2970198878/ref=tmm_hrd_swatch_0Restoring Truth and Trust: An Agenda for the Intelligent Age - https://www.amazon.com/Restoring-Truth-Trust-Agenda-Intelligent/dp/2970198835/ref=tmm_pap_swatch_0 #KlausSchwab #IntelligentAge #ArtificialIntelligence #FutureOfWork #LifelongLearning #FourthIndustrialRevolution #AI #Longevity #FutureOfEducation #DigitalTransformation #HumanCentricAI #Leadership #Innovation #GlobalEconomy #SystemsThinking #FutureOfSociety #EducationReform #AIRevolution #TechnologyTrends #WorkforceTransformation #PurposeDrivenLeadership #Reskilling #Upskilling #FutureTrends #PodcastSupport the show

Send us Fan MailWhat if aging isn't just biology…but also psychology - and your brain is quietly shaping how fast you age every day?Dr. Srini Pillay, MD ( https://drsrinipillay.com/ ) is a Harvard-trained psychiatrist, brain researcher, entrepreneur, author, and expert in the science of human potential, resilience, and longevity.Dr. Pillay previously served as Assistant Professor of Psychiatry at Harvard Medical School and directed both the Outpatient Anxiety Disorders Program and the Panic Disorders Research Program in Brain Imaging at McLean Hospital, one of the world's leading psychiatric institutions.Over the course of his career, Dr. Pillay has focused on understanding how the brain shapes performance, creativity, emotional health, leadership, and even biological aging. His work bridges neuroscience, psychiatry, technology, and human behavior - translating cutting-edge brain science into practical tools for individuals, organizations, and healthcare systems.Dr. Pillay is the co-founder and Chief Medical Officer of Reulay ( https://www.reulay.com/ ), an AI-driven digital therapeutics and mindset technology company focused on healthy longevity, stress reduction, and human performance. He is also founder of the NeuroBusiness Group ( https://nbgcorporate.com/ ), where he works with leaders and organizations around the world on brain-based approaches to innovation, adaptability, resilience, and navigating complexity in the age of AI.Dr. Pillay is the author of several influential books including Tinker Dabble Doodle Try ( https://www.amazon.com/Tinker-Dabble-Doodle-Try-Unfocused/dp/1101883650 ), which explores the neuroscience of creativity and the untapped power of the brain's unconscious processing systems.Today, we'll explore the fascinating intersection of neuroscience, psychobiology, longevity, mindset, AI-powered therapeutics, creativity, and the future of human performance - and ask how our thoughts, attention, and environments may be shaping our biology far more than we realize.Important Episode Links - Reulay: https://www.reulay.com/mindset?via=dr-sriniImplementing The Science Behind the Law of Attraction: https://loacourse.drsrinipillay.com/specialDr. Srini Pillay Socials:IG: https://www.instagram.com/drsrinipillay/LinkedIn: https://www.linkedin.com/in/drsrinipillay/Meta: https://www.facebook.com/SriniPillayMDX: https://x.com/drsrinipillayTikTOK: https://www.tiktok.com/@dr.srinipillaySubstack: https://drsrinipillay.substack.com/?utm_campaign=profile_chipsDr. Srini Pillay Free products:Ideal Self Guide: https://nas.com/drsrini/products/ideal-self-guideWeekly newsletter on mind-body connection: Sign up here: https://drsrinipillay.com/Dr. Srini Pillay Paid products:Book: Tinker Dabble Doodle Try: https://www.amazon.com/Tinker-Dabble-Doodle-Try-Unfocused/dp/1101883650Book: Life Unlocked: https://www.amazon.com/Life-Unlocked-Revolutionary-Lessons-Overcome/dp/1609611462#Neuroscience #Longevity #HumanPotential #MindsetMatters #Psychobiology #BrainHealth #AgingScience #Healthspan #MentalHealth #StressManagement #AIHealth #DigitalTherapeutics #Neuroplasticity #FutureOfHealth #HealthTech #WellbeingScience #PerformanceScience #MindBodyConnection #LongevityScienceSupport the show

Send us Fan MailDogs can detect explosives, narcotics, missing persons, and even disease. But what if their greatest superpower isn't finding things - it's sensing molecular changes inside the human body long before symptoms appear? Today we're exploring whether the canine nose may hold the key to the next generation of cancer diagnostics.Itamar Bitan is the Co-Founder of Dognosis  ( https://www.dognosis.tech/ ), a pioneering company working to unlock one of nature's most extraordinary sensing systems - the canine nose - and combine it with cutting-edge brain-computer interfaces and machine learning.Driven by a passion for both human health and working dogs, Itamar brings together an unusual blend of expertise spanning elite military operations, canine behavior, disease detection, and technology innovation. He spent nearly four years serving in Oketz, the Israeli Defense Forces' elite special operations K9 unit, where he worked as both a combat soldier and commander, developing deep expertise in canine training, scent detection, and high-pressure operational environments.Following his military service, Itamar became the first employee and Head of Operations at Dog-Prognose, a groundbreaking Israeli startup focused on disease-detection dogs, helping advance the use of canine scent detection for medical applications.Today, at Dognosis, Itamar and his team are pursuing an ambitious vision: digitizing canine scent perception itself. By combining the remarkable olfactory abilities of trained dogs with brain-computer interfaces, artificial intelligence, and machine learning, Dognosis aims to create a new generation of diagnostic tools capable of detecting diseases - including cancer - earlier, faster, and potentially more accurately than ever before.Itamar's work raises profound questions about the future of medicine, the untapped biological capabilities of animals, and how technology may help us translate nature's most sophisticated sensing systems into scalable healthcare solutions.#CancerDetection #ArtificialIntelligence #AI #BrainComputerInterface #BCI #CancerResearch #EarlyDetection #Dogs #MedicalInnovation #Biotechnology #FutureOfMedicine #HealthcareInnovation #MachineLearning #PrecisionMedicine #LiquidBiopsy #CanineDetection #CancerScreening #HealthTech #Diagnostics #SciencePodcast #STEM #Innovation #FutureTech #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailHe spent decades interviewing some of the toughest athletes on the planet. Meanwhile, he was quietly battling a condition that at times covered nearly his entire body. Today, for the first time, Paul shares the story behind the story.Paul is an 11-time Emmy Award-winning sports television producer whose career has taken him behind the scenes of some of the biggest moments in sports and entertainment.For more than sixteen years, Paul served as a senior producer, helping create acclaimed documentaries, television series, and feature programming seen by millions. Along the way he has interviewed and produced stories featuring some of the most recognizable names in sports and popular culture, including Tom Brady, Peyton Manning, Michael Jordan, Steph Curry, Charles Barkley, Deion Sanders, Eminem, and many others.Paul has led large-scale productions, won multiple national Emmy Awards, and directed feature-length documentaries, including projects that reached the top of the streaming charts.But behind that successful career was a challenge most viewers never knew about.Since childhood, Paul has lived with severe eczema, a chronic inflammatory skin condition that at times affected nearly his entire body. The condition impacted everything from sleep and travel to confidence, comfort, and everyday interactions. For years he largely kept those struggles private while continuing to work in some of the most visible and demanding environments in professional sports media.Today we'll talk about Paul's remarkable career in sports storytelling, what it was like navigating a visible chronic condition in a culture that often celebrates toughness and silence, and why broader conversations around men's health need to include conditions that affect quality of life, mental well-being, and self-confidence.Important Episode Links - Nemluvio Web Page - https://www.nemluvio.com/Nemluvio Safety Information - https://www.galderma.com/sites/default/files/2024-12/Nemluvio_Dual%20PI%20for%20website%2013Dec24.pdfNemluvio FDA Approval Press - https://www.galderma.com/news/galderma-receives-us-fda-approval-nemluvior-nemolizumab-patients-moderate-severe-atopic#MensHealth #EczemaAwareness #ChronicIllness #InvisibleIllness #AtopicDermatitis #MentalHealth #HealthAndWellness #SportsMedia #NFLFilms #Resilience #QualityOfLife #HiddenStruggles #Nemluvio #MensHealthMonth #HealthAwareness #PersonalStory #PodcastInterview #ProgressPotentialPossibilities #PPPShow #ChronicDisease #InspirationSupport the show

Send us Fan MailWe spend enormous amounts of time trying to extend life - but almost no time learning how to deal with the fact that it ends. And that gap is creating enormous suffering for families.Dr. Marianne Matzo, Ph.D., FAAN is a nationally recognized gerontologist, hospice nurse, educator, researcher, and advocate whose career has been devoted to one of the most universal - and often avoided - human experiences: dying.Dr. Matzo is a Fellow of the American Academy of Nursing, one of the profession's highest honors, and served as Professor and the Frances E. and A. Earl Ziegler Chair in Palliative Care Nursing at the University of Oklahoma Health Sciences Center. Over a distinguished academic career, she helped shape the field of palliative care education, co-authoring the first palliative care nursing textbook published in the United States, now in its fifth edition.Dr. Matzo's research has explored everything from end-of-life communication and assisted dying to sexual health among people living with serious illness, helping to advance both clinical practice and public understanding.Following her retirement from full-time academia, Dr. Matzo launched the nonprofit organization Everyone Dies ( https://every1dies.org/ ), dedicated to public education about serious illness, dying, death, and bereavement. Through podcasts, educational resources, and children's literature, she is working to transform how Americans think about mortality and helping families navigate some of life's most difficult conversations with greater confidence, compassion, and clarity.Today we'll explore Dr. Matzo's remarkable career, the evolution of hospice and palliative care, why our culture struggles to discuss death, and what it would mean to build a society that approaches the end of life with wisdom rather than fear.#DeathEducation #PalliativeCare #HospiceCare #EndOfLifeCare #GriefSupport #Healthcare #MedicalEthics #Aging #Gerontology #AdvanceCarePlanning #HospiceNurse #PublicHealth #Longevity #DeathPositive #SeriousIllness #Caregiving #Wellness #Medicine #Bioethics #EveryoneDiesSupport the show

Send us Fan MailWhat if we could recreate the inside of a star - not in theory, but inside a laboratory on Earth using the world's most powerful lasers?Dr. Mario Manuel, Ph.D. is a plasma physicist and laser-science researcher at whose work sits at the frontier of fusion energy, laboratory astrophysics, high-energy-density physics, and advanced laser diagnostics. Trained in applied plasma physics and aerospace engineering, Dr. Manuel has spent his career developing new ways to visualize and understand the extreme electromagnetic environments created when ultra-powerful lasers interact with matter.Dr. Manuel's research has spanned some of the most ambitious scientific efforts underway today - from inertial fusion energy and plasma-instability control to recreating supernova-like shock waves in the laboratory and generating ultra-intense gamma-ray and particle beams using petawatt-class lasers. Early in his career, Dr. Manuel helped pioneer advanced proton-radiography techniques capable of imaging invisible electric and magnetic fields inside laser-produced plasmas, work that opened new windows into the turbulent physics that can either enable or destroy fusion reactions.Today at General Atomics ( https://www.ga.com/ ), Dr. Manuel is involved in next-generation high-repetition-rate laser systems and the GALADRIEL ( https://www.ga.com/galadriel/ ) facility, where researchers are developing the automation, diagnostics, AI-driven optimization, and rapid experimental capabilities that may ultimately make practical laser fusion energy possible. His work also bridges into laboratory astrophysics, where miniature laser-driven plasmas are used to study the same collision-less shocks, turbulence, and magnetic-field generation processes that occur in supernova remnants and other extreme cosmic environments.With collaborations spanning facilities such as the National Ignition Facility in Livermore, California, and the OMEGA Laser Facility in Rochester, New York, along with partnerships across the fusion-energy and laboratory-astrophysics communities, Dr. Manuel represents a new generation of interdisciplinary scientists using ultra-powerful lasers not only to pursue practical fusion energy, but also to recreate and study some of the most extreme physical processes in the universe. From plasma turbulence and magnetic-field generation to collision-less shocks and high-energy particle acceleration, his work connects the quest for clean energy with the physics of stars, supernovae, and cosmic plasmas.#fusionenergy #nuclearfusion #nationalignitionfacility #laserscience #plasmaphysics #labastrophysics #supernova #gammaRays #particlephysics #inertialconfinementfusion #cleanenergy #futureofenergy #deeptech #sciencepodcast #generalatomics #livermore #omegaLaser #highenergyphysics #physics #aiinscience #fusionbreakthrough #scienceinterviewSupport the show

Send us Fan MailWhat if modern medicine has become incredibly good at saving children's lives…but society still hasn't figured out how to help many of those children truly live afterward?Dr. Nicholas Holekamp, MD is the Chief Health Transformation Officer at Ranken Jordan Pediatric Bridge Hospital in St. Louis ( https://rankenjordan.org/about-us/leadership/nicholas-holekamp-md/ ), one of only a handful of pediatric bridge hospitals in the United States and the only one of its kind in Missouri ( www.RankenJordanFoundation.org ).For more than two decades, Dr. Holekamp has helped pioneer a radically different approach to caring for children with complex medical conditions through Ranken Jordan's innovative “Care Beyond the Bedside” model - a philosophy built around a deceptively simple but powerful idea: children heal better when they are active, engaged, social, and out of bed.Under Dr. Holekamp's leadership, Ranken Jordan evolved from a small 26-bed pediatric nursing facility into a nationally recognized 60-bed specialty hospital focused on helping medically complex children transition safely from intensive hospital care back to home and community life.A graduate of Dartmouth College and Saint Louis University School of Medicine, Dr. Holekamp completed his pediatric residency at Cardinal Glennon Children's Medical Center before joining Ranken Jordan in 2000. Along the way, he has become one of the leading voices in pediatric complex care and transitional medicine.Dr. Holekamp's work has combined clinical care, hospital transformation, and research - including published studies demonstrating how movement, play, environment, and family-centered care can improve outcomes for medically fragile children while potentially reducing healthcare utilization and costs.Dr. Holekamp has been recognized for both his medical leadership and community impact, including receiving the Missouri Foundation for Health's Dr. Corinne Walentik Leadership in Health Award and delivering a TEDxStLouis talk on the future of pediatric healing and healthcare transformation.Today, as Chief Health Transformation Officer, Dr. Holekamp is focused on sharing the lessons of Ranken Jordan with hospitals and healthcare systems across the country - challenging long-held assumptions about what healing environments for children should actually look like.#Pediatrics #ChildrensHospital #MedicalEthics #HealthcareInnovation #PediatricCare #Neurodevelopment #ChildrenWithMedicalComplexity #HealthcarePodcast #Medicine #PediatricMedicine #HospitalInnovation #CriticalCare #Bioethics #FamilyCenteredCare #HealthcareLeadership #MedicalResearch #VentilatorCare #Rehabilitation #PediatricRehabilitation #FutureOfHealthcare #HealthcareSystems #MedicalTechnology #ProgressPotentialPossibilities #HealthcareTransformation #PediatricICUSupport the show

Send us Fan MailOver the last several years, artificial intelligence has transformed from a speculative concept in healthcare into one of the most heavily funded movements in pharmaceutical and biotech history.But in 2026, the conversation is changing. The question is no longer whether AI can generate molecules, analyze pathology slides, or identify patterns in clinical data. The real question is: which of these technologies can survive the complexity of biology, regulatory scrutiny, clinical validation, and real-world deployment?Today we're joined once again by returning guest Bill Taranto, President and Founding Partner of the Merck Global Health Innovation Fund ( https://www.merckghifund.com/ ), alongside Managing Director, Dr. David Rubin, who brings a deep scientific background spanning molecular biology, oncology, precision medicine, and digital health investing.Together, Bill and David sit at a unique intersection of pharma strategy, venture investing, translational science, and clinical deployment. Through investments across AI-driven drug discovery, precision medicine, diagnostics, and digital health - including early involvement with companies like PathAI - they've had a front-row seat to what's actually working in AI-enabled healthcare…and what still breaks down when these systems encounter real-world medicine.Today we'll explore where AI is genuinely creating value across the pharmaceutical stack, why some approaches are beginning to achieve meaningful validation, what investors and pharma companies are now demanding beyond hype, and how entirely new experimental models - from organoids to AI-native biology platforms - may reshape the future of drug development.#AI #ArtificialIntelligence #DrugDiscovery #Biotech #Pharma #HealthcareAI #PrecisionMedicine #DigitalHealth #Oncology #PathAI #Roche #Biology #MachineLearning #BiotechInvesting #VentureCapital #Merck #DigitalPathology #ClinicalTrials #FutureOfMedicine #LifeSciences #AIHealthcare #MedicalInnovation #Biotechnology #CancerResearch #PrecisionOncology #Bioinformatics #HealthcareInnovation #Pharmaceuticals #MedTech #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailFor decades, agriculture and energy were treated as separate worlds. But what happens when farms become part of the global energy infrastructure? Ofer Haviv joins us to discuss the rise of castor as a next-generation industrial crop, the future of sustainable aviation fuel, and how AI-driven biology is transforming agriculture itself.Ofer Haviv is CEO of Casterra ( https://casterra.co/ ) and longtime President and CEO of Evogene ( https://evogene.com/ ), one of the pioneers in computational biology and AI-driven agricultural innovation.For more than two decades, Ofer has helped lead the transformation of crop science from traditional breeding into a data-driven discipline powered by predictive biology, artificial intelligence, and advanced genomics. He played a key role in Evogene's spin-off from Compugen in 2002 and has guided the company through its evolution into a global computational biology platform with applications spanning agriculture, human health, industrial biotechnology, and sustainable materials.Today, Ofer also serves as CEO of Casterra, an Evogene subsidiary focused on transforming castor farming into a scalable industrial platform for the future bioeconomy. Through elite castor seed varieties and integrated farming solutions, Casterra is helping address growing global demand for sustainable feedstocks used in biofuels, aviation fuel, lubricants, polymers, cosmetics, and other bio-based industries.With increasing pressure on the world to decarbonize transportation, strengthen energy security, and develop more sustainable industrial supply chains, Casterra's work sits at the convergence of agriculture, climate technology, and renewable energy innovation.Ofer holds a degree in Economics and Accounting from Tel Aviv University and is a Certified Public Accountant in Israel.#OferHaviv #Casterra #Evogene #Biofuels #SustainableAviationFuel #SAF #ClimateTech #Agriculture #AgTech #Biotech #AI #ArtificialIntelligence #ComputationalBiology #RenewableEnergy #GreenEnergy #FutureOfEnergy #IndustrialBiotech #Castor #SustainableFarming #EnergyTransition #Bioeconomy #CarbonNeutral #FutureTech #ClimateInnovation #CleanTech #Aviation #JetFuel #SustainableTechnology #FoodTech #PrecisionAgricultureSupport the show

Send us Fan MailEvery once in a while, a simple question changes medicine forever.For decades, chronic and traumatic wounds were among the most frustrating problems in healthcare. Doctors could clean wounds, dress wounds, and hope for healing - but many patients remained trapped in cycles of infection, inflammation, and failed recovery.Then came one deceptively simple idea:  What happens if you apply vacuum?That question led to the creation of Vacuum Assisted Closure - better known worldwide as V.A.C.® Therapy ( https://www.solventum.com/en-us/home/medical/advanced-wound-care/negative-pressure-wound-therapy/vac-therapy/ ) - developed by plastic surgeon Dr. Louis Argenta and biomedical engineer Dr. Michael Morykwas ( https://www.renovoconcepts.com/michaelmorykwasbio ).The technology transformed wound care by using controlled negative pressure to remove fluid, stimulate blood flow, encourage tissue growth, and accelerate healing. What began as a bold experiment evolved into one of the most important advances in modern medicine, helping more than 20 million patients worldwide - from burn victims and diabetic patients to wounded soldiers returning from Iraq and Afghanistan.For this groundbreaking work, Drs. Argenta and Morykwas were inducted into the National Inventors Hall of Fame ( https://www.invent.org/inductees/michael-morykwas ).Today, we're joined by Dr. Michael Morykwas - bioengineer, inventor, scientist, and lifelong tinkerer - to explore the origins of this revolutionary technology, the science behind mechanobiology and wound healing, the long road from prototype to global adoption, and what the future of regenerative medicine may look like next.Photo Credit - National Inventors Hall of Fame #MichaelMorykwas #VACtherapy #WoundHealing #RegenerativeMedicine #Mechanobiology #BiomedicalEngineering #MedicalInnovation #NegativePressureWoundTherapy #TissueEngineering #HealthcareInnovation #PlasticSurgery #Bioengineering #MedicalBreakthrough #Inventor #NationalInventorsHallOfFame #RegenerativeScience #MilitaryMedicine #FutureOfMedicine #MedTech #SciencePodcast #InnovationPodcast #HealthcareTechnology #StemCells #WoundCare #MedicalScienceSupport the show

Send us Fan MailFor years, T cell therapies have transformed blood cancers - but solid tumors have remained one of the hardest problems in medicine. Now a new company called Deck Bio believes the issue isn't just finding a better target...it's that cancer may never have been a single-target disease in the first place.Dr. Jack Silberstein, Ph.D. is the Founder and CEO of Deck Bio ( https://deck.bio/ ), a biotechnology company developing next-generation T cell engager therapies designed to address one of the most persistent challenges in solid tumor immunotherapy: antigen heterogeneity and immune escape.Deck Bio's platform takes a multi-target approach, engineering T cell receptors to simultaneously recognize multiple peptide-MHC (pMHC) complexes, with the goal of improving both tumor specificity and durable anti-tumor activity while reducing the on-target/off-tumor toxicity that has limited earlier T cell engager strategies.Prior to founding Deck Bio, Dr. Silberstein trained as an immunology Ph.D. at Stanford University, where he was a Bio-X interdisciplinary fellow, and later worked at Johns Hopkins University on early clinical and translational oncology studies, including work on AR-V7 as a resistance biomarker in prostate cancer and early immune checkpoint combination trials. His background spans both deep immunology and real-world clinical translation in oncology.Dr. Silberstein joins us following Deck Bio's recent preclinical presentation at AACR 2026 in San Diego, where the company shared early data on its multi-pMHC targeting strategy.#DeckBio #JackSilberstein #Immunotherapy #CancerResearch #TCellEngagers #Biotech #AACR2026 #SolidTumors #CancerTherapy #TCellTherapy #PrecisionMedicine #Oncology #TCRTherapy #CancerInnovation #Biotechnology #ImmuneSystem #CellTherapy #CancerBreakthrough #SyntheticBiology #FutureOfMedicineSupport the show

Send us Fan MailWhat if the next pandemic could be identified, diagnosed, and targeted with programmable CRISPR therapeutics before it spreads globally? That's exactly what Seek Labs is trying to build.Jared Bauer is CEO of Seek Labs ( https://seeklabs.com/ ), a clinical-stage TechBio company developing an integrated platform that combines AI-driven genomic intelligence, rapid field diagnostics, and CRISPR-based therapeutics designed to identify and potentially counter emerging pathogens faster than ever before.In a world where outbreaks can spread globally before traditional systems even identify the threat - as we saw with COVID and more recently with delayed hantavirus confirmation cases - Seek Labs is asking a bold question: what if diagnostics and therapeutics could be programmed and deployed at the speed of software?Jared is also Chairman of BioHive Utah ( https://www.biohive.com/ ), one of the fastest-growing life science ecosystems in the United States, and has spent his career at the intersection of biotech innovation, AI, diagnostics, and public health preparedness.We discuss AI-driven drug discovery, CRISPR therapeutics, programmable outbreak response, biodefense infrastructure, and what the next generation of pandemic preparedness may actually look like.#SeekLabs #JaredBauer #CRISPR #AI #Biotech #PandemicPreparedness #BioDefense #Diagnostics #Therapeutics #GeneEditing #SyntheticBiology #InfectiousDisease #FutureOfMedicine #HealthcareInnovation #PrecisionMedicine #Biotechnology #BARDA #ARPAH #DiseaseSurveillance #TechBio #OutbreakResponse #Biosecurity #AIinHealthcare #MedicalInnovation #PodcastSupport the show

Send us Fan MailMost people assume national security delays are about technology.They're not.  They're about paperwork - and it can take up to two years just to deploy software the government already wants.Andrew Black is a national security entrepreneur, cybersecurity executive, and emerging technology strategist whose career has sat at the intersection of AI, defense, cyber risk, and global security operations.Andrew is currently the CEO of Kovr.ai ( https://kovr.ai/ ) an AI-native cyber compliance platform focused on one of the biggest bottlenecks in modern national security: getting software and cloud systems authorized for use in highly regulated and classified environments. Kovr.ai is using AI to automate complex compliance frameworks like FedRAMP and CMMC, helping organizations become “ATO-ready” (Authority to Operate) in minutes rather than months.  Andrew also now serves as Chief Strategy Officer of Fortreum  ( https://fortreum.com/ ) which recently acquired Kovr.aiBefore joining Kovr.ai, Andrew led emerging technology initiatives at Amazon Web Services (AWS), where he worked with government leaders on next-generation capabilities spanning artificial intelligence, generative AI, quantum computing, high-performance computing, edge systems, and space technologies.Andrew's career has also included leadership roles at Gartner, advisory work with the Krach Institute for Tech Diplomacy at Purdue, venture investing with NextGen Venture Partners, and teaching national security and data analysis as adjunct faculty at Georgetown University Walsh School of Foreign Service.Earlier in his career, Andrew worked in counter-terrorism, threat modeling, and risk analytics, building data-driven systems to allocate anti-terrorism resources and anticipate geopolitical instability in frontier and conflict-affected regions.A graduate of University of St Andrews and Georgetown University, Andrew has spent two decades helping government and industry navigate increasingly complex technological and security landscapes - and today he's focused on transforming how AI can accelerate trust, compliance, and operational readiness across the defense ecosystem.#AI #Cybersecurity #NationalSecurity #DefenseTech #FedRAMP #CMMC #ATO #ArtificialIntelligence #GovTech #CyberCompliance #CloudSecurity #KovrAI #DoD #ZeroTrust #EmergingTech #Startup #MachineLearning #CyberDefense #FutureOfAI #GovernmentTechnologySupport the show

Send us Fan MailEvery product you buy has a journey - but for most companies, that journey is basically invisible until something goes wrong.Today we are diving into one of the most overlooked - yet absolutely essential - pieces of global commerce: the pallet. Every year, billions of products move across the world sitting on these simple platforms, but despite the rise of AI, IoT, robotics, and digital supply chains, the pallet itself has remained largely unchanged for decades.Our guest today is trying to change that.Joining us is Rodrigo Castro, Co-Founder and President of Adaptive Pallet Solutions ( APS - https://adaptivepalletsolutions.com/ ), a Philadelphia-based company building what they call a “supply chain intelligence platform” powered through smart pallets. APS leases 100% recyclable plastic pallets embedded with IoT sensors capable of tracking location, temperature, humidity, shock, load status, theft, and other real-time logistics data across global supply chains.Rather than treating pallets as disposable infrastructure, APS is transforming them into connected data assets - helping Fortune 500 companies gain visibility into food, pharmaceutical, retail, and logistics operations while also reducing waste and improving sustainability.Rodrigo brings a fascinating mix of finance, infrastructure, and operational thinking to the problem. Prior to APS, he worked in investment banking at PNC Bank within the Financial Institutions Group, was an investor at LL Funds focused on specialty finance and fintech, and is also Co-Founder and Managing Partner at 912 Capital Partners, where he focuses on major secular growth themes including manufacturing, electrification, digital infrastructure, and supply chains.Rodrigo is also a graduate of Amherst College, where he studied Economics and German, and spent time studying abroad at the University of Vienna.Today we'll explore how something as humble as the pallet became a massive blind spot in modern logistics, why the future of supply chains may depend on real-time physical intelligence, and how connected infrastructure could reshape everything from pharmaceuticals and food safety to retail and global trade resilience.#SupplyChain #Logistics #Innovation #IoT #SmartPallets #ColdChain #PharmaLogistics #FoodSupplyChain #RetailTech #InsurTech #AIinLogistics #Sustainability #CircularEconomy #IndustrialIoT #DigitalTransformation #WarehouseAutomation #SupplyChainVisibility #FutureOfLogistics #TechInnovation #AdaptivePalletSolutionsSupport the show

Send us Fan MailWhat if medicines could actually “decide” when and where to activate inside the body? MIT-trained synthetic biologist Dr. Jacob Becraft, Ph.D. is building programmable therapies that behave less like traditional drugs…and more like biological software.Dr. Becraft is Co-Founder and CEO of Strand Therapeutics ( https://www.strandtx.com/ ), a company pioneering what may become one of the next great frontiers in medicine: programmable mRNA therapeutics.Long before mRNA became a household term through COVID vaccines, Dr. Becraft and his colleagues at MIT were developing what has been described as the world's first synthetic biology programming language for mRNA - technology designed not simply to deliver genetic instructions, but to create logic-driven therapies capable of making decisions inside living cells.Now Strand is translating that vision into cancer therapeutics, with early clinical data from its lead candidate STX-001 showing responses in patients with advanced solid tumors who had exhausted conventional options - including evidence of systemic immune activity and even complete responses.Beyond the science, Jake is also a leading voice in synthetic biology, biotech entrepreneurship, and the future relationship between software, biology, and medicine.#StrandTherapeutics #JacobBecraft #SyntheticBiology #mRNA #ProgrammableMedicine #CancerImmunotherapy #Immunotherapy #Biotech #PrecisionMedicine #GeneTherapy #SyntheticBiologyEngineering #FutureOfMedicine #Oncology #CAR_T #mRNATherapeutics #Bioengineering #IL12 #RNA #MIT #CellTherapy #Longevity #Biotechnology #MedicalInnovation #NextGenMedicine #CancerResearch #AIinBiology #HealthcareInnovation #GeneticMedicine #ScientificBreakthrough #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailBladder cancer treatment is entering a new era. From gene therapy and bladder preservation to AI-assisted diagnostics and the challenge of detecting “hidden” CIS, Dr. Ravi Chauhan, MD, FACS breaks down the technologies and clinical decisions reshaping urology in 2026.Dr. Ravi Chauhan, MD, FACS ( https://conradpearson.com/our-specialists/ravi-d-chauhan-m-d-facs/ ) is a board-certified urologist, fellowship-trained uro-oncology specialist, and one of the leading voices in advanced kidney and bladder cancer care in the Mid-South.Born and raised in Memphis, Tennessee, Dr. Chauhan graduated Cum Laude from Rhodes College with a degree in molecular biology before earning his M.D. and completing both his general surgery internship and urologic surgery residency at The University of Tennessee Health Science Center. He joined the Conrad Pearson Clinic in 2005 and has since become a recognized leader in the treatment of advanced bladder and kidney cancers, with numerous publications and presentations to his name.Dr. Chauhan's path into medicine was deeply personal. Inspired by watching his father practice medicine and witnessing the profound impact physicians can have on patients and families, he developed a philosophy centered on treating every patient with the same compassion, respect, and attention he would want for his own family.In addition to his expertise in surgical urology and uro-oncology, Dr. Chauhan has become increasingly focused on one of the biggest challenges in modern bladder cancer management: identifying and treating high-risk non–muscle invasive bladder cancer - or NMIBC, particularly  carcinoma in situ - or CIS , which can often be difficult to detect in routine clinical practice.Today, we'll discuss the evolving diagnostic landscape for CIS, why missed or under-recognized disease can significantly impact treatment decisions, and the growing importance of collaboration between urologists and pathologists. We'll also explore how community urologists are navigating these rapidly evolving standards of care, the future of precision bladder cancer management, and what it means for patients facing this disease.We'll also discuss bladder-sparing approaches, including Adstiladrin® (nadofaragene firadenovec-vncg), an intravesical gene therapy for adults with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC with CIS, with or without papillary ( https://www.adstiladrin.com/ ).ADSTILADRIN should not be used in patients with hypersensitivity to interferon alfa or its components, and individuals who are immunosuppressed or immune-deficient should not handle or receive the therapy. Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.The most common adverse reactions include urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in urine. Patients should consult their healthcare provider regarding all medications and report any side effects. Please see full Prescribing Information  ( https://d2hu1op93domjx.cloudfront.net/wp-content/uploads/sites/12/2026/03/24101239/ADSTILADRIN-USPI-Mar.2026-CLEAN.pdf ) for additional details.#BladderCancer #Urology #CancerResearch #BladderCancerAwareness #NMIBC #CarcinomaInSitu #CIS #UroOncology #GeneTherapy #CancerTreatment #PrecisionMedicine #BCG #BladderPreservation #MedicalInnovation #Oncology #CancerCare #Immunotherapy #HealthcareInnovation #UrologistSupport the show

Send us Fan MailDrowning is the leading cause of death for children ages 1 to 4 in multiple countries - yet it receives only a fraction of the attention of other public health crises. Why?Acacia Landfield is Associate Director, Principal Investigator, and Director of Policy & Implementation Science at The Drowning Research & Injury Prevention Policy Institute ( DRIPPI - https://www.drippi.org/ ), a multidisciplinary nonprofit consortium focused on reducing drowning deaths through research, education, systems thinking, and policy innovation.Acacia brings together an unusually broad background spanning public health, international diplomacy, education, implementation science, and aquatic safety. A lifelong swim coach and water safety educator, she has spent more than 25 years working across injury prevention, public policy, and community education, with a mission to address one of the world's most overlooked public health crises: childhood drowning.Acacia's work focuses on what she calls “universal basic aquatic competency” - the idea that early, gentle, developmentally informed water exposure can fundamentally change drowning outcomes across entire populations. Her research explores everything from breathing mechanics and motor learning in the water to the unintended downstream effects of flotation devices and inequities in aquatic infrastructure.Acacia is also helping reframe drowning prevention as part of a much larger conversation around climate resilience, disaster preparedness, urban planning, and health equity. As a 2024 Presidential Road Safety Scholar with the American Public Health Association, and an active contributor to climate and disaster preparedness initiatives, she is pushing for drowning prevention to be treated not as a niche issue, but as a core pillar of public health policy worldwide.Before co-founding DRIPPI and launching her research initiative SASE, Acacia held leadership and strategy roles at Massachusetts Institute of Technology, Harvard University, and the U.S. Department of State, where she worked on international education, diplomacy, and policy initiatives across multiple countries and sectors.Acacia holds degrees from Yale University and San José State University, is completing her MPH, and plans to pursue a DrPH focused on implementation science and injury prevention.Today, we'll explore why drowning remains one of the leading causes of death for children worldwide, why many current prevention models may be incomplete, and how a systems-level rethink of aquatic literacy could potentially save tens of thousands of lives each year.#DrowningPrevention #WaterSafety #AquaticLiteracy #Swimming #PublicHealth #ClimateResilience #ChildSafety #AquaticCompetency #DRIPPI #AcaciaLandfield #InjuryPrevention #SwimSafety #Aquatics #GlobalHealth #ClimateChange #ImplementationScience #AquaticEducation #SwimmingLessons #Parenting #HealthPodcast #Longevity #BrainHealth #DisasterPreparedness #HealthInnovation #WaterCompetencySupport the show

Send us Fan MailWhat if the biggest problem in nuclear energy isn't reactor technology…but paperwork, regulation, and institutional bottlenecks? Today we explore how AI could compress nuclear deployment timelines from decades to years.Kevin Kong is founder and CEO of Everstar ( https://everstar.ai/ ), a company building advanced AI reasoning systems designed to accelerate the deployment of nuclear power and modernize the infrastructure workflows surrounding the industry.Now when most people think about nuclear innovation, they think about reactors, fusion, uranium, or next-generation fuels. But Kevin and his team are focused on a very different problem - the massive institutional and cognitive bottlenecks that slow nuclear projects down. We're talking about years of regulatory review, millions of pages of compliance documentation, fragmented engineering systems, workforce shortages, operational complexity, and the enormous burden of coordinating safety-critical infrastructure at scale.Everstar is building AI systems intended to transform that process - converting dormant technical documentation into what they call ‘active intelligence.' Their platform combines advanced reasoning models, retrieval systems, multimodal AI, computer vision, and eventually robotics and sensor integrations to help accelerate engineering review, licensing, inspections, compliance workflows, and industrial decision-making inside the nuclear ecosystem.The company recently participated alongside the Department of Energy, Idaho National Laboratory, Argonne National Laboratory, and Microsoft in the DOE's Genesis Mission initiative - where Everstar demonstrated AI-assisted nuclear licensing workflows capable of generating NRC-style regulatory documentation in a fraction of the traditional timeline. The project has become an early example of how reasoning-based AI systems may begin operating inside some of the world's most highly regulated industries.Kevin's own background is unusually interdisciplinary. Before entering nuclear, he worked across software engineering, AI infrastructure, data systems, mobility technology, venture investing, and crisis logistics. He held leadership roles at companies including Bird and Rakuten, co-founded the AI data platform Hyperquery, studied economics and organizational sociology at Harvard University, and later pursued nuclear engineering coursework at Massachusetts Institute of Technology.In this conversation, we explore:- why nuclear energy may be essential for the future of AI and civilization-scale energy demand;- how reasoning systems could accelerate infrastructure deployment;- whether AI is ready for high-consequence industries like nuclear;- the future of AI-assisted licensing and compliance;- digital twins, robotics, and autonomous inspections;- the growing energy demands of AI datacenters;and - the deeper question of whether the true bottleneck to civilization is no longer physics…but institutional throughput itself.#NuclearEnergy #ArtificialIntelligence #AI #NuclearPower #EnergyAbundance #SMR #SmallModularReactors #NuclearInnovation #FutureOfEnergy #EnergyInfrastructure #AIInfrastructure #KevinKong #Everstar #AdvancedAI #NuclearEngineering #CleanEnergy #EnergySecurity #MachineLearning #IndustrialAI #Datacenters #FusionEnergy #TechPodcast #FutureTech #EnergyTech #Infrastructure #Robotics #ComputerVision #AIRevolution #NRC #EnergyTransitionSupport the show

Send us Fan MailFor decades, the beauty industry focused on creams, serums, and surface-level solutions. But what if aging skin is really a reflection of something much deeper happening inside our cells? Today's guest is François Vix, a longtime global beauty and wellness executive who has spent more than four decades at the intersection of skincare science, redox biology and oxidative stress research, and healthy aging.François began his career inside some of the world's biggest beauty and consumer health companies, holding senior leadership roles at L'Oréal, Lancôme, Biotherm, Johnson & Johnson, Neutrogena, and RoC Skincare, where he helped scale global brands across North America, Europe, Asia, and Latin America. Along the way, he became increasingly fascinated by a deeper scientific question: are we truly addressing the biological root causes of skin aging and inflammation - or simply treating the visible symptoms?That question eventually led François towards a new look at the science of redox biology, oxidative stress and the body's endogenous antioxidant systems, particularly the enzyme Superoxide Dismutase, or SOD - one of the body's first-line defenses against free radical damage.In 2001, François founded ISOCELL Laboratories ( https://www.glisodin.org/ ), focused on developing clinically studied approaches, including the GliSODin nutricosmetics brand, to supporting the body's own antioxidant defense mechanisms. Over the last two decades, the company has expanded internationally into more than 50 countries and has explored applications spanning skin health, inflammation, immune function, pigmentation disorders, and longevity science.Today, François speaks widely about redox biology and oxidative stress, integrative dermatology, and what he calls “beautyspan” - the idea that the future of beauty may increasingly be tied to cellular resilience, metabolic health, and healthy aging from within.#FrançoisVix #GliSODin #OxidativeStress #FreeRadicals #Longevity #Beautyspan #AntiAging #Perimenopause #MenopauseHealth #SkinHealth #HealthyAging #Mitochondria #RedoxBiology #Antioxidants #SOD #SuperoxideDismutase #IntegrativeMedicine #FunctionalMedicine #SkinLongevity #Biohacking #Healthspan #Inflammaging #LongevityScience #BeautyScience #Hormones #WomensHealth #CellularHealth #AgingResearch #WellnessPodcast #IraPastorSupport the show